MedWatch

Sitemap

Genmab strikes deal with German biotech companyNovo Ventures invests millions in Bavarian Nordic rival Bavarian and other RSV companies navigating uncharted territoryDanish company prepares to take the psoriasis market by storm – seeks FDA approvalNovo Nordisk develops new mechanical insulin pill with star researchers from MITBavarian will use own money to start RSV trials, but is still seeking a partnerMIT researcher behind mechanical insulin pills prepared for new Novo partnershipsAmerican senators behind over-the-counter hearing aid law demand answers from the FDA: When will the sales guidelines be ready?Leo Pharma looks towards billion-dollar market after phase III successSale of hearing aids in the US exceeds 4 million devices for the first timeEnochian Biosciences has a market cap of $238 million, but researchers doubt the company: "There is no scientific documentation to base their claim on"New CEO backs Leo Pharma's transformation: "It is definitely the right strategy"Leo gambles on partner’s skin cancer drug even though option agreement is not yet settledLeo Pharma boss on newly purchased drug: "It is a very cleverly designed antibody"Biogen hopes for breakthrough at Danish Medicines Council after new price drop: "We have taken significant action"EU advocates general says Lundbeck's DKK 700 million fine is justifiedLeo Pharma makes new push for older treatment with brand new trial conceptBiogen shocked by Danish medicines council doubt over SpinrazaNovo Nordisk bets on innovative insulin: "Many doctors said we were crazy"MC2 prepares for US launch by the end of the yearLeo Pharma wants to be first in US with hand eczema treatmentOwner foundation to sell Leo Pharma stakeLeo Pharma to cut up to 650 positionsLeo Pharma poised to market new drug every 2-3 yearsLeo Pharma poised to post DKK billion figure into San Francisco drug: "We're waiting for the trial results"Novo Nordisk to suppliers: Switch to green transport or lose us as a customerFDA plans new sales channel for hearing aids in autumnColoplast CEO: "It's important for me we don't turn into a company, where it only works if we invented it"ALK launches tablet vaccine for tree pollen allergy The life science industry has a sexism problem – and no one knows the scaleColoplast executive: We've had sexism cases, and they've been handled with zero toleranceEli Lilly executive on crucial tirzepatide data: "It is a very exciting time"Eli Lilly prepares obesity efforts with future hope – goes down same path as Novo NordiskNovo Nordisk unsure about chance of reaching upper growth target: "This would require significant changes"Hungarian factory initiative brings Coloplast one step closer to sustainability goalsColoplast CEO on expectations: "There are many swing factors"Novo Nordisk acquires collaborative partner for USD 1.8bnALK CEO after upgrade: "In spite of Covid-19, ALK is on a roll – I'm really proud"Researchers behind Alzheimer's study: GLP-1 drugs show great promisePandemic kicked off ALK's digitization processStartup aims for tailwind after Alzheimer's study involving Novo drugVaccine researcher lays head on the block: "If Pfizer's Covid-19 vaccine works, so will ours"Covid-19 creates uncertainty for Zealand Pharma drug against short bowel syndromeALK gains millions from webshop – may reach the size of the firm's core marketBavarian on lacking coronavirus vaccine funding: Sponsors prioritize speed over qualityIrishwoman takes over EMA Executive Director positionAmbu ready for price war on market for single-use devicesDanish-Swedish diabetes company goes on the stock exchange in 2021GN Hearing lost ground at US VA – and so did DemantFormer Widex CEO on chairman prospects: I can deliver in every areaNovo Nordisk cuts 450 positions in the USMajor medtech supplier teams up with Copenhagen-based startupUS senators behind over-the-counter hearing aid sales legislation: Get started on sales guidelines!Moderna reveals price of coronavirus vaccineNovo Nordisk and Biomarin make peace in strife over employees and confidentialityHearing aid giants position themselves within US sales channel using new productsPhilips has grown stronger from the pandemic: This has been an organizational stress testGalecto fetches former CEO from Aimmune for board Genmab ditches drug candidateBiogen taps Danish biotech firm for collaboration on novel Lupus treatmentEU plans for better access to low-cost generics and biosimilars in new pharmaceutical strategySonova-owned hearing company plummets on top and bottom lines – survives at the mercy of ownerNovo breathes life into Alzheimer's speculations after executive huntDemant launches new flagship productColoplast CEO: I can calmly declare that the best times are ahead of usIncyte expands in Scandinavia and plans to more than double its employeesNovo Nordisk loses court case against Sanofi over Danish press statementDanish Business Authority's decision causes Lundbeck to downgrade guidanceExperiences from Covid-19 will create success for Demant's virtual product launchJanssen turns to Danish startup for pill to replace the need to inject drugsGenmab: Janssen applies for approval for lung cancer drug in the USOrphazyme opens US headquarters in Chicago and appoints executivesNew CEO gets rid of a number of Ambu executivesNovo Nordisk submits obesity drug for FDA approvalMillion-dollar investment leads AGC Biologics to start new staff hunt – needs up to 300 new employeesNovo Nordisk completes acquisition of Emisphere TechnologiesNovo Nordisk withdraws press statement – had misleading marketingEli Lilly candidate shows weight loss at 11 percent in phase III trialFormer Novo Nordisk employee plans to revolutionize market for insulin pensCoronavirus vaccines are lucrative businessSonova receives FDA approval for new technologyInvestcorp buys Danish Sanos GroupDemant turns up outlook after better-than-expected salesNovo after crucial data from competitor: Welcomes drug R&DAmbu CEO: "We need an innovative speed that's hard to compete with"Orphazyme board on CEO changes: She had an old-fashioned management styleMedia: Europe aims for vaccine approval on Dec. 23Zealand Pharma disappoints with diabetes drug in phase IIIAmbu lands new single-use endoscope contract with US GPONovo Nordisk to start phase III trial with tablet for Alzheimer'sNovo Nordisk files for EU approval for obesity treatmentNovo Holdings and CEO Kutay on the hunt for billion kroner investmentY-mabs closes deals in China and Europe for the firm's two drugs against pediatric cancerNovo Nordisk places stakes on Alzheimer's treatment: hunts for success on the pharmaceutical industry's boulevard of broken dreamsBavarian Nordic secures second part of smallpox vaccine order from the USDrugmakers agree to halve prices to secure access to ChinaThe Lundbeck Foundation's new strategy: CEO wants to buy more firms like Lundbeck, ALK and FalckHemophilia firm from former Novo employee secures millions from Novo SeedsBavarian Nordic defies new failure and maintains efforts in cancer areaBiotech stocks ready for more Covid-19 results in first quarterSanofi is battle-ready: "We welcome competition, not least from our great colleagues at Leo Pharma"EU to help vaccine manufacturers expand productionNovo Nordisk applies for label extension for diabetes treatmentAscendis submits FDA application to start cancer trialEU to help vaccine manufacturers expand productionBavarian Nordic will supply smallpox vaccines to three European countriesGenmab initiates phase III trial with drug against cervical cancerNovo Nordisk selects first drug candidate in Dicerna collaborationPfizer readies to compete against Ascendis and Novo Nordisk: Submits weekly growth hormone to FDAWidex family secures power over WS AudiologyEli Lilly skyrockets following positive Alzheimer's dataCalm Novo Nordisk following Brexit: We had five years to prepare"After finding out half a million tests were far from enough, we had to work out how to produce five million"WSA puts new man in charge of US brandNovo CEO Lars Fruergaard Jørgensen hopes for Eli Lilly's future successColoplast CEO urged to take action: Release the billions!Novo ceases payments to US politiciansAfter decades Novo Nordisk approaches historic milestone for obesity marketLeo Pharma goes head to head with Janssen in new psoriasis trialUS hospital sales of Novo Nordisk's hemophilia drug dropped in DecemberEuropean Medicines Agency: Leaked documents have been manipulatedNovo Nordisk seeks extended approval for diabetes drug in the USGermany to start registering single-use scopes – Ambu to take advantageAmbu surpasses Q1 expectations and hits significant milestoneAmbu to raise USD 212m in new capitalAmbu will use pandemic to kick in door to new marketsWS Audiology books new billion-kroner deficit – lost EUR 243m during virus yearExpert committee recommends new Novo Nordisk growth hormone for EU approvalWS Audiology loses USD 600m across two years – still withholds net profit guidanceGN Hearing introduces new product family in lowest price rangeBavarian Nordic is ready to produce Covid-19 vaccines for other companiesFrance says Europe vaccine strategy safer than U.K.’sColoplast surpasses guidance and sets out to launch share buyback programEU chief says she was responsible for gaffe over vaccine exportsMads Krogsgaard Thomsen resigns from Novo NordiskNovo Nordisk expects 5-9 percent sales growth in 2021Vaccine disputes may harm pharmaceutical industry's reputationNovo Nordisk CEO: Strategy remains constant after Krogsgaard's departureColoplast CEO on buying spree: "Something has to happen"Novo Nordisk's CFO expects US growth boost this yearLundbeck beats forecasts considerably in Q4Lundbeck plans for carbon neutrality by 2050EU poised to beat cancerLundbeck on new climate plan: aims for carbon neutrality long before 2050Ambu expands US contracts with single-use endoscopesNovo Nordisk kicks off phase III trial program for new insulin hope EU cancer plan applaudedLundbeck: acquisitions must be well consideredSanofi's eczema drug is four-time blockbusterSanofi's diabetes business affected by Q4 falling prices and Covid-19EU president recognizes responsibility and failures in vaccine purchaseNovo Nordisk CEO: Semaglutide could create serious obesity treatment market Demant report looks to future following two horrifying fiscal yearsPost-pandemic healthcare trends will turn, says SEB's new biotech portfolio lead Coloplast considers increasing tax payment transparency after criticismALK has decent growth forecast in sightDemant plans to grow 23-27 percent after two awful yearsDemant to boost transparency on differing business developmentsDemant forecasts better 2021 than pre-corona and hacker attackAnalyst: Demant's guidance reflects improved market conditionsEli Lilly CFO leaves after "exhibiting poor judgment"ALK winds up with Q4 deficit despite record-breaking revenueLundbeck gets top marks for engaging suppliers in climate effortsDemant CEO's wages barely changed in Covid-stricken yearFood allergy venture to boost ALK's growthPharmaceutical company makes commitments to EU antitrust chiefGenmab and Seagen submit cancer drug application to US FDAGN Hearing expects 2021 comeback after tough yearPoliticians want their hands on pharmaceutical companies' vaccine patentsLundbeck CEO's pay cut in half in 2020In spite of Covid-19 lock-downs and sent-home employees, GN have held on to R&D effortsTeva plans to take over major chunk of migraine marketEMA clarifies: No Russian application for vaccine approvalGN Hearing got DKK 103m in state support in 2020 – and laid off a few employeesALK invested DKK 1bn in US breakthrough: "It didn't pan out the way we'd hoped"Retail stakes proved costly for Demant during first coronavirus lockdownOlympus' endoscope sales retreatAmbu CEO on stream of launches: "Won't be easy, but we're building an ecosystem"Analyst: Eli Lilly considers Alzheimer's submission after phase IIEMA starts rolling review of Curevac vaccine against Covid-19Danish PM is willing to finance vaccine productionBiotech firm raises USD 80m for pharmaceutically treating hearing lossNovo Nordisk increases transparency on tax paymentsLundbeck hunts for new success drugs in niche diseasesLundbeck's hopes have high costs: "You won't see us reaching that level in the future"Europe prepares a mutant Covid vaccine plan to fight the crisisAlmirall acquires rights to new psoriasis drug in EuropeOlympus looks into patient injuries from duodenoscopesMillions of vaccines waiting in warehousesEMA starts safety-related review of obesity drugNovo Nordisk CEO on his legacy: What I spend most of my time onEli Lilly's Tirzepatide shows reductions in blood sugar levels and weightAnalyst: New Eli Lilly drug doesn't throw Novo Nordisk's Ozempic curveballGenmab-developed sclerosis treatment beats competition in small injector pen studyLeo Pharma finds new head of UK and Ireland marketsExperts: Mandatory release of patents highly unlikelyFerring divests testosterone drug in new dealRoche to embrace new technologies early onCochlear states that its momentum has improvedGlobal antimicrobial fund expands with USD 140m and CEOUS biotech to submit new psoriasis treatment to the FDA in summerFlourishing trade activity in life science industryGenerics companies get green light for Lundbeck drugAlmirall predicts positive 2021 development of psoriasis productAnalyst emphasizes 2021 guidance in Genmab fiscal reportGenmab appoints chief medical officerNovo Holdings buys Canadian life science companyFormer utility boss nominated for new Novo Nordisk board memberWSA gets Google Country Director for boardAlmirall closes gap in product portfolio through commercialization agreement with MC2Commentator views former Ørsted CEO as potential Novo Nordisk chairmanGenmab to take at least one new product to phase III in 2021Genmab CEO: Arbitration might be concluded in 2021Novo's dark forecasts have been disproved: "We're stronger in the US than we've been in many years"MC2 Therapeutics aims to lead psoriasis marketEU leaders want to secure vaccine productionFormer FDA top dog joins board of Parkinson's firmGenmab's CEO pulls in DKK 37.3m salary – has shares worth DKK 1.6bnNovo Nordisk plans to invest DKK 500m in expanding tablet production facilitiesGenmab CEO: Three products may turn into five this yearHorizon Therapeutics to make blockbuster out of Genmab drug in 2021Coloplast CEO: Digital Denmark has proven worth during Covid-19Astrazeneca's CEO and colleagues grilled at EU HearingNovo Nordisk Pharmatech lands record profits in 2020 Biomarin awaits crucial approvals and flat growth in 2021Novo Nordisk appoints new head of drug discoveryTop news from MedWatch this weekOrphazyme recruits new CEONovo Nordisk Pharmatech to open new sales office in USFinance analyst: Novo's sales from obesity drugs may grow earlier than anticipatedPfizer may present new growth hormone in 2022Boehringer Ingelheim inks third collab in four years with Danish biotech companyBoard on new Orphazyme CEO: He has the management style we wantOrphazyme: Anticipated product approval to secure transformational yearGenmab and Lundbeck implement sustainability goals in executive incentive programsFinancial analyst raises share price target for Lundbeck due to Rexulti potential Fraudsters offer EU vaccinesOrphazyme CFO: 2021 will be the decisive yearDanish PM open towards the idea of establishing vaccine factoryAmbassador views Teva CEO as important player in potential vaccine allianceNovo Nordisk lines up for May Alzheimer's trialGlobal investment firm KKR buys Danish biotech firm share for USD 100mFujifilm starts expanding Danish production facilityDenmark and Israel have discussed vaccine collab for almost a yearThe EMA starts rolling review of Russian vaccineEli Lilly surpasses Novo's golden diabetes drugAnalyst: Lilly doesn't overshadow semaglutide in spite of strong dataNovo Nordisk chair foresees pressure on pharmaceutical industryDenmark, Israel and Austria to look into the possibility of a joint vaccine productionNovo Nordisk chairman on top wages: "It's a hard balance to strike"EU Commission initiates formal investigation of TevaTop news from MedWatch this weekBavarian Nordic presents new preclinical data for Covid-19 vaccineFinance analyst: Eli Lilly deals hard blow to Novo Nordisk with new dataNovo Nordisk chairman: We must make heaps of strong leaders for ourselves – and for other companiesAnalyst views clinical results as central to Bavarian Nordic's external financingBavarian Nordic still hopes to find financing for Covid-19 vaccineBavarian eases up on categorical statements on Covid-19 vaccine financingDanish government hesitant to rein in EU health response even though industry calls for itBiomarin's previously rejected hemophilia drug gets special status at the FDANovo Nordisk hires former Director General of DMABavarian Nordic sells discount shares to help fund Covid-19 vaccineFund chief to kickstart fundamental changes in antibiotics marketGN gave off shares to Demant in VA sales channelNovo Nordisk tests grand acquisition in phase III trialUK denies EU allegation that vaccine exports have been bannedBavarian Nordic on new capital raising round: Covid-19 was the decisive factorMedia: EU is major vaccine exporter in spite of supply problemsDenmark suspends Astrazeneca vaccinationsWS Audiology balances out male-dominated top management with new coworkerZealand Pharma CEO before possible approval: We can take major leapAscendis powers ahead on capital spendingNovo Nordisk chairman on lacking diversity: "I haven't done enough"Lundbeck wants Merck EVP as board memberTop news from MedWatch this weekBavarian Nordic's 2021 will be full of developmentEMA starts rolling review for Eli Lilly's Covid-19 treatmentNovo Nordisk EVP: "When you're the little brother you're still part of the family. This is important to remember"Cochlear gets US clearance for new implant – first to have streaming for both Android and IphoneThe Novo Nordisk Foundation discusses Danish vaccine production with governmentNovo Nordisk has three biopharma blockbusters on the wayMore attacks on Lundbeck's big sellerFollowing recalls and delays, Novo Nordisk kicks off smart insulin pen launchJefferies valuates Bavarian Nordic's Covid-19 projectGalecto ditches high doses in phase II trialNovo Nordisk Foundation chair warns against new state-funded vaccine productionLundbeck poaches CSO from US biotech firmEMA: We're firmly convinced of the benefits of the Astrazeneca vaccineGlooko raises just under DKK 190m in financing round with Novo Nordisk as major investorNovo Holdings appoints new head of responsible investmentsBioporto CEO holds Covid-19 test at arm's length: "Could be everything or nothing"Former Novo employee alleges sexual harassment, discrimination: success meant flirting with bossNew Lundbeck exec to get firm's next research leg startedGN chair sees divisional collaborations as advantageNovo Nordisk and Gilead expand partnership Vaccines seen protecting against Brazil strain in Oxford studyNovo Holdings beats records in 2020 and earns DKK 29bnMoment of truth for Coloplast's US ventureNovo increases fatty liver efforts: "We've seen some highly convincing data"EU and US to zoom in on pharmaceutical industry mergersTop news from MedWatch this weekCanada orders more smallpox vaccines from Bavarian NordicCovid-19 created many attractive opportunities for Novo Holdings in 2020Leo Pharma struggles with lawsuit in the USVaccines hope takes Bavarian Nordic's share price to more than 300 DKKZealand Pharma gets approval for low blood sugar treatmentFDA refuses to file Novo Nordisk applicationNordic Capital posts millions of euros in Leo Pharma – gets owner's share at under 25 percentLeo Pharma elaborates on 2030 strategy after new capital injectionZealand Pharma sends rescue pen on the market in late JuneLeo Pharma failed on the top line yet succeeded on profit in 2020On 24 occasions employees warned Lundbeck management of foul playLeo Pharma's board now has one person lessTrust in Astrazeneca vaccine is dropping in EuropeEU vaccine rules may disrupt global supply, including to alliesCompetition authority interferes with Takeda's deal with Danish OrifarmEU Court of Justice turns down Lundbeck appeal – fine still standsNovo Holdings has worked large Convatec investment for four years: "Things don't happen overnight"Lundbeck disappointed over verdict – fine paid in 2013Danish bank: Lost appeal case paves way for new compensation claims against LundbeckVirtual Novo Nordisk AGM: Headed for 2025 goal, but pandemic caused fragile public financial situationBavarian Nordic's CBO quitsEU chief: Astrazeneca must adhere to EU contract to exportNovo Nordisk Pharmatech finds new CEO – choice falls on board memberTop news from MedWatch this weekCHMP recommends Novo Nordisk's Saxenda for adolescentsOrphazyme fails trial in muscle wasting disease Democrats want insulin producers investigatedTrial with Danish coronavirus therapy is prioritized in the UKColoplast gets crucial US deal for ostomy productAnalyst on US Coloplast contract: Important contract – volumes will probably increaseOrphazyme CFO on failed trial: "Highly disappointing and highly surprising"Novartis gets approval for Genmab drug against multiple sclerosis in EuropeNew Pharmatech CEO expects larger external sales – but this won't weaken relationship with Novo NordiskCEO after US contract: "For the first time ever, Coloplast has equal access to the market"Orphazyme share recovers somewhat after diveGenmab chief on sclerosis drug launch: Novartis prioritizes usFDA approves new larger production setup for Genmab drugOrifarm got Covid-19 discount on Takeda purchases: "The timing was in our favor"GN intensifies goal: Plans to have at least 25 percent female leaders by 2025Astrazeneca fully understands Danish vaccine pause: "It's about maintaining trust in the vaccines"When the world shut down, Roche went all-in and carried on its research programsOne in two Danes would opt out of Astrazeneca vaccineFDA investigates infection rates for endoscope use – Olympus and Karl Storz recur in reportsBavarian receives USD 28m order from JanssenHearing aid CEO predicts big rebound after virus year and massive costs shutting down subsidiaryAnalyst: Ebola order has positive signal value for Bavarian's investorsDanish Covid-19 therapy shows promise in phase I trialM&A advisors: "We've never seen such investor interest in this service before"Genmab drug becomes more accessible in the USHearing aid company fetches million dollar figure in capital raising roundEMA sticks to the recommendation of Astrazeneca's covid-vaccineNovo Nordisk tests own mobile app in phase III trial with insulin hopeLundbeck drug hope moves closer to moment of truthDanish Health Authority awaits Danish study results before giving verdict on AstrazenecaEli Lilly has to wait a while longer for FDA verdictKesimpta's complicated developmental path has shaped Genmab's approach to partnershipsZealand Pharma will soon launch first drugNovo puts million-dollar figure towards television commercialsFrance wants to mix vaccines – Denmark considers the sameTop news from MedWatch this weekFDA grants new Genmab drug priority review status New Orphazyme CEO has great ambitions: Wants to create new GenmabAuthorities are closely monitoring blood clot cases following vaccinesAnalyst: Genmab's progress with the FDA sends a positive signalGN lost market shares from veterans in March – againNovo Ventures company plans to fetch USD 127.5m on the US stock exchangeLundbeck carries on Rexulti study after new analysisOrphazyme investor following muscle wasting disappointment: "Now everything has to run smoothly in 2021"Analyst: Genmab share price may doubleLundbeck executive remains confident about Alzheimer's drug after new analysisBoehringer Ingelheim and partner launches stage II trials for NASH and obesityPension fund criticizes Genmab salary packagesGN Hearing maintains guidance – still predicts 25 percent growth for 2021Danish authorities: Astrazeneca vaccine to be discontinued in DenmarkInvestors demand tax transparency from GN Store NordGenmab CEO on possible settlement in dispute with Janssen: "I have no comment"Astrazeneca on vaccine skepticism: "Many forget it's a non-profit project"Here is why the Danish Health Authority stopped using the Astrazaneca vaccineWHO: Denmark considers sharing Astrazeneca vaccine with developing countriesGilead scores new FDA approval for drug obtained in billion-dollar purchaseWS Audiology is the no. 1 applicant for patents within hearing aid industryDanish government makes vaccine production a priority in new life science strategyMorgan Stanley: 12 new product launches will pave the way for AmbuEU likely to decline new vaccine deals with Astrazeneca and J&JTop news from MedWatch this weekHealth organizations see danger in Denmark’s decision to stop using Astrazeneca vaccineRoche publishes new sclerosis data to keep Novartis at bay ALK gains important approval on difficult US marketSydbank: Expanded ALK approval is good newsDenmark discusses vaccine swap with other countriesWS Audiology plans to list subsidiaryJanssen receives new approval for Darzalex in CanadaAlnylam is at the new frontier of medicines: "It will have the same impact on the industry as antibodies"Janssen had better Darzalex sales than expected in Q1EU politicians plan to focus on Europe's obesity problemVerathon gets European approval for single-use productRoche reports slightly better sales than predicted in Q1FDA requires more data from Y-mabsAnalyst: Listed subsidiary may pave the way for WSA and take chunk out of massive debtNovo Nordisk initiates trial with obesity-treating tabletNovo Nordisk wants obesity tablet to have same effect as injectionEU prepares to file lawsuit against AstrazenecaLundbeck drug shows significantly improved functioning in major depressive disorderFDA postpones plan for new hearing aid sales channel – againAnalysts lose confidence in Biogen Alzheimer's approvalEU Commission denies report on Astrazeneca lawsuitCHMP recommends Leo Pharma's tralokinumab for approval in atopic dermatitisLeo Pharma executive on EU progress: This is a huge milestone for usEU won't take up option to buy more Astrazeneca vaccinesUS authorities investigate new death following J&J vaccinationTop news from MedWatch this weekCHMP recommends eight medicines for approvalGN Hearing kicks off trial with self-fitting hearing aidEU expects new portal for clinical trials will be ready in early 2022Sanofi hits bullseye in phase III trial of treatment for RSVEU initiates lawsuit against Astrazeneca for breach of contractMSD sets carbon neutrality goalLundbeck eyes major breakthrough for brain diseasesÖssur advances in all areas after Covid-19-affected yearEli Lilly lowers guidance for 2021Bavarian Nordic may start producing covid-19 vaccines next yearNovartis chief sees remote-work hybrid persisting after pandemicY-mabs files for EU approval for pediatric cancer drugSanofi's diabetes business shrinks againSanofi's Dupixent sales grow 45 percent in Q1Boston Scientific had better results in Q1 than predictedEli Lilly on tirzepatide data: Surpasses our expectationsPfizer buys Amplyx Pharmaceuticals from LundbeckfondenBavarian Nordic on vaccine candidate: Preclinical data indicates broad protectionCancer firm Adcendo raises EUR 51mDanish government will allow gradual vaccine production in DenmarkTop news from MedWatch this weekFDA issues complete response letter to Leo Pharma's tralokinumab Pfizer and Biontech request to expand authorization for vaccine for adolescentsLundbeck backs Trintellix with new dataBiomarin gets ready for launch in second half-year of 2021Olympus launches line of single-use scopesAnalyst predicts that covid-19 will still affect DemantAnalyst: Novo Nordisk's year may start with zero growthDemant raises financial guidance for 2021New top product and Philips range have won market shares for DemantWSA ready to launch new Signia product platformAnalysts to home in on expenses in Genmab's Wednesday fiscal reportFrench reforms and US vaccinations benefit Demant in corona-struck timesALK's Q1 better than predicted on top and bottom lineNovo Nordisk beats expectations – upgrades outlookAGC Biologics will produce chronic gout treatment for Horizon TherapeuticsChinese authorities have approved Novo Nordisk's OzempicNovo Nordisk CEO on disappointing Rybelsus sales: Influenced by lockdownALK powers ahead on crucial market following new regulations for prescribing medicineDifficult conditions in the UK and postponed operations expected to affect Q2 for ColoplastGN Hearing's top line took a dive in Q1 – firm maintains 2021 guidanceGenmab spent more than DKK 1 billion in Q1Novo Nordisk expands obesity business in spite of obstaclesWSA raises guidance in first-ever public H1 reportColoplast raises EBIT margin guidanceGN flagship product gets off to a bad start with war veterans: "It is an unfortunate cocktail"Genmab is going through a growth spurt and expands on three continentsLeo Pharma's board chair steps down US exercises option for Bavarian Nordic smallpox vaccineWSA feels a change in the wind: Sees benefits of transparency after 65 yearsGenmab CEO on legal fight with Janssen: Standing up straight and fighting for what's morally and ethically rightEU splits on vaccine patent waivers to cast doubt on US planOrphazyme CEO disappointed with failed ALS trial – pins hope on other disease areaTop news from MedWatch this weekOlympus targets carbon neutrality by 2030Novo Nordisk recalls medicine samples following Texas power outagesEU countries are in no hurry to waive vaccine patentsLundbeck: Pandemic and currency woes have led to setbacksCovid-19 costs Coloplast USD 33m in extended court casesSwiss hearing aid giant makes EUR 200m acquisition – poised for new US sales channelLundbeck loses top-line terrain but surpasses expectationsAlmirall starts the year with solid growthEU readies new lawsuit against Astrazeneca over vaccinesGN executive does not envy sister firm's booming successAnalyst believes in continued progress for AmbuLundbeck bets on four core products during hard yearAmbu gets US approval for new productAmbu fails to live up to revenue forecastsElectronics firm presents long-awaited hearing solutionAnalyst on new Bose hearing aid: "Won't disrupt Danish manufacturers"Tough competition forces innovation at AmbuZealand Pharma CEO: "A very busy time for us"Stock market unease causes listing of WSA subsidiary to be postponedPrivate equity firm Gilde eyes growing potential in ScandinaviaNovo Nordisk's semaglutide shows improved mental and physical wellbeing as obesity treatmentALK awaits crucial adrenaline data in 2021 and plans to submit FDA application in less than three yearsSix companies show interest in vaccine production in DenmarkTop news from MedWatch this weekLife science executives: We can feel the lack of traveling salespeopleNovo Nordisk working on new digital solution for treating patients with insulinAstellas enters into strategic collaboration with Kyoto UniversityWSA wants Widex products back in US sales channelWSA exec quits – internal candidate takes overNovo drug ziltivekimab meets primary endpoint in inflammatory biomarker trialSonova affected by fluctuating currencies in 2020/2021Leo Pharma starts phase III hand eczema trialALK expands digital venture with US partnershipSwiss hearing aid giant comes out on top after covid-19 crisisNovo Holdings takes the lead in investment in new Asian companyXellia pays steep price for factory delaysTeva CEO on decimated share price: "It's rational enough from a market point of view"Swiss take steps to guarantee supplies of EU medical productsUS health authority reprimands large pharmaceutical firms after disagreement on drug discountsNovo Nordisk looks into repurposing millions of used insulin pensBiomarin presents new five-year data for hemophilia gene therapyEli Lilly plans to submit tirzepatide application at the end of the yearLundbeck to push transport sector in greener directionAnalyst: New study confirms that Eli Lilly's tirzepatide is a good productY-mabs enters into partnership with Uruguayan firm to launch cancer drugs in South AmericaNovo Holdings co-leads Swiss funding roundBiotech firm gets Chinese patent on plant substance cocktail for diabetes, obesity and fatty liver preventionGoogle app will help detect skin ailmentsAudientes builds up momentum and prepares for Q3 launchNovo Nordisk to issue Euro medium term notes worth up to EUR 5bnColoplast starts new colostomy leakage trialTop news from MedWatch this weekEMA gives positive opinion on Genmab's Darzalex in combination treatmentGenmab partner gets approval for lung cancer drug from Duobody platformNovo Nordisk prepares to launch diabetes tablet in IndiaColoplast recalls urology productEli Lilly sues HHS in strife over discounted drugsBoston Scientific gets CE marking for single-use bronchoscopeNovo Nordisk launches smart insulin pen in DenmarkGlobal tax agreement could prompt Novo Nordisk to take tax payments elsewhereNovo Holdings contributes to USD 540m investment in US health platformIO Biotech puts down roots in USA and hires new CSOEU demands Astrazeneca court order to supply vaccine dosesNew regulation means stricter requirements for medtech firmsBavarian Nordic maintains guidance for 2021Pentax obtains EU approval for single-use scopeDarzalex performs well in Janssen's rare disease studyBavarian Nordic partners up with Dynavax on hepatitis B vaccineNew sales agreement is another piece of Bavarian Nordic's commercial puzzleNovo Holdings completes third investment in Asia in one monthNovo Nordisk successfully prices Euro medium term notes worth EUR 1.3bnNovo Nordisk risks insulin shock on Chinese marketTravel restrictions bite Bavarian as rabies vaccine sales plungeCarb-X investment gives Snipr Biome validation before going to clinicTop news from MedWatch this weekAscendis increases expenses shortly before moment of truthNovo Nordisk resubmits higher-dosage Ozempic application to the FDALundbeck CEO Deborah Dunsire wants to prioritize mental health in the wake of covid-19FDA approves migraine pill as preventative treatment Nordic politicians encouraged to place antibiotic resistance higher on the agenda316 European residents experienced blood clots following hotly debated vaccineNovo Nordisk enters collaboration with Heartseed on cell-based treatmentFDA approval of semaglutide could help Novo Nordisk access unexploited obesity marketMicrobiome venture can start production in Denmark and SwitzerlandStallergenes gets European approval for dust mite allergy tabletAnalysts: Stallergenes' approval may expand the market for allergy tabletsPentax forms Chinese partnership for single-use scopesNew partnership may pave the way for first Novo Nordisk stem cell treatmentEU deal forces large firms to share tax informationNovo Holdings and Healthcap launch new biotech firmAnother Genmab drug from Janssen receives breakthrough therapy designationGN and Demant lose VA market shares againBoehringer Ingelheim and Zealand Pharma's Nash candidate fast tracked by FDAGenmab to collaborate with Californian biotech company on three drugsOrphazyme's hour of reckoning approaches: "Its existence is threatened if it gets a clear no"Bavarian Nordic hunts for best covid-19 vaccine production setup – may drop current manufacturerAnalyst: Pentax partnership might lead Ambu to new marketGN launches Jabra hearing aid at CostcoLack of news leaves Lundbeck high and dryGN CEO: Jabra's strong brand is perfect for CostcoEU’s trade response to pandemic stops short of vaccine IP waiverDenmark sends 358,000 surplus vaccines to KenyaDrugmakers in China take aim at pharma’s lucrative cancer fightersAudientes CEO: We have the perfect product for the future OTC channelG7 ministers: Global tax agreement in sightTop news from MedWatch this weekFDA approves Novo Nordisk's semaglutide as obesity treatmentNovo Nordisk EVP: Semaglutide can double obesity business in few yearsDemant and GN ramp up investments – with money to spareWHO gives further support to Bavarian Nordic and Johnson & Johnson's Ebola vaccineLaunch of obesity drug will be Novo Nordisk's fastest everFate of Biogen’s stock rides on Alzheimer’s drug decisionObesity drug has no competitors on unexploited market, says Novo NordiskBiogen passes FDA test for Alzheimer's medicineWS Audiology joins Science Based Targets initiativeBiogen's US Alzheimer's drug may also come to EuropeFDA heavily criticized by independent institute over Biogen approvalThree global giants consider vaccine production in DenmarkNovo Nordisk enters into collaboration with Danish crispr firm SniprBogus drugs and medical equipment abound in EuropePfizer gives Danish PM cold shoulder: rejects idea of starting vaccine production in DenmarkDementia professor on new Biogen approval: The first small step towards new developmentsHearing company enters into first partnership in big venture in IndiaDanish companies: A minimum tax rate has advantagesBiogen to start shipping new Alzheimer's drug in two weeksTeva and Eli Lilly scrap over migraine drug rightsWHO: Europe is far from safe from covid-19Biontech plans to produce mRNA vaccines in AfricaNewly established firm puts down roots in DenmarkFDA advisors quit after approval of Alzheimer's medicineAnalyst calls Orphazyme's 300 percent value jump "strange and noteworthy"Orphazyme CEO on trading explosion: "We have no idea what is going on"Top news from MedWatch this weekEquity trader on Orphazyme surprise: "It's a bit like Gamestop all over again"Bavarian Nordic to supply UK with monkeypox vaccinesFDA extends review period for Ascendis Pharma's first drugOrphazyme launches investigation into dramatic and mysterious share price roller coasterIncyte's atopical dermatitis cream delayedOlympus gets new Regional Managing Director for the NordicsJanssen publicizes more Darzalex data Novo Holdings acquires diagnostics company for USD 564mNovo Holdings plans to enter ChinaFDA agrees to meeting with Enochian over HIV therapySage Therapeutics depression drug disappointsDemant won major market shares at VA in MayFormer Emisphere investors sue following sale to Novo NordiskAnalyst: Demant's Oticon More generates strong VA figuresEMA to be beefed up for future crisesLarge shareholder sells some Orphazyme shares shortly before vital FDA ruling, general partner denies connectionNovo Nordisk enters into research collaboration with Lumen BioscienceOlympus hires former Ambu CEOSonova gains two new board membersBiogen partner calls for global Alzheimer's effortOlympus on former Ambu CEO's advisory role: "He will be a big asset"Novo Holdings hot on diagnostics: This is the key to unlocking two of the largest healthcare issuesUtility Therapeutics prepares FDA applicationBavarian Nordic: Vaccine production almost came to DenmarkMore disappointment for Orphazyme as FDA rejects Niemann Pick C applicationOrphazyme cuts guidance following FDA setbackTop Orphazyme figure on FDA rejection: "It is very disappointing and very unexpected"EMA hesitates over flunking Curevac vaccine despite missed targetUS OTC hearing aid channel back on Department of Health agendaOrphazyme CEO silent on potential firings in wake of FDA rejectionTop news from MedWatch this weekNovo Nordisk CEO's pay sets itself apart on especially one pointEU and Astrazeneca each declare lawsuit victoryOrphazyme not seeking fresh capital despite reduced cash position FDA approves new Ambu productSeries of setbacks have not caused Orphazyme CEO to consider departingColoplast sees potential in RussiaBavarian Nordic CEO frustrated with lack of reply on financial support for vaccine candidateLeo Pharma's new drug for atopic dermatitis receives EU approvalRoche's digital health venture boosted by pandemicNovo Nordisk expands collaboration with US app companyFinancial analyst: Novo Nordisk's obesity treatment could triple marketEMA continues to review link between myocarditis and coronavirus vaccinationLeo Pharma starts study of eczema tablet for nettle rashJanssen gets expanded authorization for Genmab's Darzalex in EUBiogen criticized in the US over price of new Alzheimer's drugLeo Pharma receives UK approval for AdtralzaGoldman Sachs reduces share in Orphazyme and drops below 5 percent boundaryUS dermatology top boss moves to Danish biotech firmY-mabs delayed again in the USAmgen gets Japanese authorization for migraine drugNovo Holdings sees golden opportunity in dialysis company, contributes to USD 245m investmentOticon Medical gets FDA approval for cochlear implantLilly gets sought-after FDA designation for Alzheimer's candidateZealand Pharma sends blood sugar drug to US marketStallergenes Greer production back to full capacity after years of limited activityOticon president satisfied with FDA approval: "A huge milestone"Pharmacosmos launches cell therapy market offensiveAustralian firm acquires Denmark's largest cannabis companyECDC wants to bring forward second jab to tame variantCHMP recommends eight new drugs for approval – one cancer drug rejectedTop news from MedWatch this weekOrphazyme to get rid of two thirds of employeesFDA recommends single-use bronchoscopesSanofi reveals detailed timeframe for RSV candidateAmbu gets recommendation from FDA, analyst doubts effectOticon Medical General Manager after US FDA approval: It's a competitive situationNovo Nordisk wants to innovate in new ways to find curesVifor Pharma gets new CEOTwo main factors behind Sanofi's dialog with Danish authoritiesSanofi to establish mRNA vaccine center with 400 employees AGC Biologics contacted minister over Danish vaccine collaboration before PM announcementEli Lilly welcomes competition for cheap insulin in USNovo Nordisk's analog insulin will be sold cheaply in WalmartNovo Nordisk sticks to cautious obesity sales goalWSA raises ESG ambitionsZealand Pharma President of US Operations on first launch: Timing was our most important goal Novo Nordisk closes deal on technology platformFerring appoints Lars Rebien Sørensen as new chairmanEQT and owner family divest Fertin Pharma to Philip Morris International for DKK 5.1bnLeo Pharma appoints former Novo Nordisk CFO as new chairman of the boardEMA second-in-command retires after 25 years at the organizationAmbu downgrades due to covid-19 and logistical challengesNew chairman to prepare Leo Pharma for IPO with new launches and financial disciplineConflicts of interest have kept Lars Rebien Sørensen away from pharmaceutical boards – until now130 countries enter into tax reform agreementTop news from MedWatch this weekNew Coloplast Senior Vice President: MDR will guide our innovation focus in the futureBank bemused by Ambu downgradeOrphazyme investors snatched up profits before FDA failureAmbu brings plans for Mexico factory forwardBioNTech/Pfizer vaccine is less effective against Delta variantLeo Pharma to collaborate with US biotech companyLundbeck hands over former Alzheimer's candidate to privately-owned biotech companyMC2 and Almirall clear crucial obstacle to psoriasis treatment in EuropeAlmirall opens submissions for new dermatology partnershipsBoehringer and Eli Lilly meet primary endpoints in heart failure treatment studiesAmplifon expands Chinese presence in new joint ventureNovo Nordisk Pharmatech closes distribution agreement for Russia and CIS countriesAscendis moves forward with phase III drugNovo Holdings invests huge sums in the USAlmirall partner MC2 on the verge of EU victory after ten years of hard workNovo Nordisk veteran takes up CMO position at Danish-Swedish biotech companySales of Biohaven's migraine tablet exceed expectationsSanofi pays up to USD 1bn for new multiple myeloma therapyBrazilian success: SynAct Pharma scores positive results with therapy for covid-19WSA buys US retail chainFDA changes prescribing information for new Alzheimer's drugBiden starts new offensive to bring down medicine prices New Biden order criticizing hearing aid expense causes falling share pricesTop news from MedWatch this weekAnalyst: Biden attack on pharmaceutical industry seems symbolicEMA currently sees no need for Covid booster jabPharma giants see huge potential in new "super technology" for fighting a wide range of diseasesNovo Nordisk buys treatment candidate for rare disease for up to USD 1.2bnUS sees global tax agreement as beneficial for allAmplifon buys Bay Audio for DKK 2.6bnJanssen gets FDA approval for new Darzalex combination Experts: The world needs more than just mRNA vaccinesHearing industry challenger applauds Biden's price battleResearchers trick malaria parasites with new vaccineNovo Nordisk, Sanofi and Eli Lilly face court in US over insulin pricesDane overcomes Tokyo culture shock to run Lundbeck's most successful launchEli Lilly acquires biotech firm in new insulin ventureBillionaire Moderna founder and world's most cited engineer sees "pretty unlimited" potential in mRNAGenmab surpasses 1,000 employeesPharmacosmos' revenue grows by USD 16m despite corona challengesCovid vaccine makers target bottlenecks to speed up productionEli Lilly allies itself with Alzheimer's institute in phase III dementia drug trialsGN Hearing shrinks again and Denmant's growth proves short-lived on VA channelWith launches on the way in the US and EU, MC2 turns attention to the rest of its pipelineSales of Novo Nordisk's Victoza drop in USTop news from MedWatch this weekEli Lilly and Incyte's eczema treatment delayed at FDA – againPharmacosmos predicts record financial year after launches in US and ChinaPfizer executive: "It is hugely important that the world prepares itself for potential future pandemics"MC2 Therapeutics launches psoriasis cream in USSaniona borrows USD 10m for clinical studiesNovo Nordisk bets on RNA in several business areasDenmark's largest companies report huge expansions to legal departmentsEMA starts continual assessment of Sanofi's corona vaccineLeo Pharma brings in old friends and new blood for eczema treatment launchSclerosis drug developed by Genmab brings in USD 66m to Novartis during Q2Darzalex sales exceed expectations in second quarterAnalyst: Genmab may upgrade financial guidance based on Darzalex sales figuresHemab raises USD 55m for treatment of rare bleeding disordersÖssur key market sales normalize during second quarterEMA pays respects after sudden death of Research and Innovation leaderBiogen upgrades financial guidance after exceeding expectations in Q2Over half of all adults in the EU are now fully vaccinated against covid-19Lundbeck to trial migraine drug in young peopleRoche's hemophilia treatment well on the way to triple blockbuster status Top news from MedWatch this weekCHMP recommends two new drugs for approval and rejects oneCHMP recommends Moderna covid-19 vaccine for approval in 12-17-year-oldsSweden phases out AstraZeneca's covid-19 vaccineAllarity keeps streamlining pipeline – sells cancer drug for USD 18mFDA gives Saniona candidate priority statusPfizer and Biontech expand study of vaccines for childrenNordic Capital in talks to buy healthtech firm InovalonBiontech plans to examine mRNA technology for malaria vaccinesBoston Scientific reports significant growth in endoscopy business – grows 54 percentAstrazeneca shot shows no increased clot risk after two dosesGN Hearing top exec stops after 17 years – replacement found within own ranksPharma industry is discretely working against a global tax agreementPfizer upgrades guidance for sales of covid-19 vaccineInvestors: Novo Nordisk's obesity efforts will lead to growthSanofi upgrades 2021 guidance after sales of Dupixent and diabetes products increaseFDA makes historic ruling on biosimilar insulinSmith & Nephew revenue better than expected, but operating result disappointsBiomarin prepares for European approval of Ascendis competitorAmplifon doubles Q2 sales and upgrades 2021 guidance Takeda surpasses analyst forecasts in Q1Danish State Serum Institute launches world's largest investigation of late effects from covid-19ALK closes largest deal in 10 years – gets DKK 90m for partnership in China on adrenaline autoinjectorNovo Nordisk's Wegovy sells like hot cakes in the US – increases productionPfizer and Moderna raise prices for coronavirus vaccinesDanish scientists raise alarm after discovering link between Bayer drug and brain cancerPfizer launches phase III trial with RSV candidate in SeptemberAnders Dyhr Toft waves goodbye to Novo Nordisk after 18 years to become the CMO of Synact: "It's going to be more DIY-based"Eli Lilly specifies guidance for this year's revenueEU approves upscaling of Moderna vaccine in US production facilitiesLead-up to Novo Nordisk report: Growth-heavy quarter with GLP-1 focus aheadMedia: Pfizer's covid-19 vaccine will soon get full approval in the USDenmark has shipped half a million vaccines to Ukraine Novo Nordisk upgrades guidance for the rest of the yearBank analyst on Novo Nordisk report: Impressive quarter, to say the leastNovo Nordisk's new obesity drug hits 8,000-prescription mark in few weeks: Comparing with Saxenda, it took around four yearsOlympus upgrades guidance following better-than-expected reportALK nominates former Sanofi executive for board membershipOrphazyme postpones financial reportNovo Nordisk plans to test cholesterol-lowering oral solution in phase II trialTop news from MedWatch this weekUS authority increases subsidies for single-use duodenoscopes – which benefits both Ambu and Boston ScientificMajor US bank shoots way above Novo Nordisk's own goals: New obesity drug will sell for almost USD 3.5bn in 2025.Lundbeck closes RNA deal worth USD 109m with US biotech firmAstellas shakes structure of R&D division Bavarian Nordic: Covid-19 vaccine beats Pfizer's on several parameters Bavarian Nordic CEO notes progress in vaccine funding talks with Danish government ALK upgrades guidance following convincing sales and savingsJefferies fears renewed pressure on Novo Nordisk's growthLundbeck breathes life into stranded molecule to treat new diseasesAnalyst predicts progress in Demant's H1ALK increases sales in Q2, but operating result decreasesGN Hearing and Demant lose market shares in VAAnalysts predict possible 2021 guidance upgrade from DemantFDA approves single-use bronchoscope from Boston ScientificPostponed clinical trials affect ALK finances – central phase III trials have been delayedDemant closes Q2 ahead of guidance, upgrades both revenue and earnings Genmab's successful CEO dismisses retirement plans Genmab: Janssen dispute cost DKK 146m in H1Boehringer Ingelheim and Gubra send obesity drug candidate to clinical trial Demant CEO: Ketchup effect could lead to above-average growth in 2022 and 2023Demant benefits from French reform more than projectedALK acquires drug against swimmer's ear from now former US partnerBiogen's Alzheimer's drug denied support by Veteran Affairs Bose expands to whole US with new direct-to-consumer hearing aidZealand Pharma CEO: Zegalogue launch continues as planned Genmab considers vaccine requirement for staff Novo Nordisk plugs hemorrhage with lucrative Biopharm unit restored to growthEli Lilly scores positive phase III results with new eczema treatmentAmbu overture: Weakened demand and bottlenecks burden quarter Ambu's Q3 ended better than expectedAnalyst forecasts YoY quarterly growth for Coloplast following virus year Ambu joins green climate initiative Lundbeck report could trigger upgrade despite headwindCovid-19 pins geographic needles in Ambu's core business – CEO hopes for stabilization aheadAmbu launches new duodenoscope in four weeksLundbeck upgrades annual earnings guidance, cuts revenue outlook Capacity problems accelerated Ambu's construction of world's largest endoscope plant Eli Lilly in big reshuffle: Sets up new units for neuroscience and immunology New trial shows top-selling Lundbeck drug not beating placebo for borderline Coloplast notes advance for all four units, adjusts annual guidance Covid-stricken US still causing Lundbeck problemsGN Hearing disappoints despite high Q2 growth – maintains annual guidance Coloplast seeks more US catheter acquisitions: "We want increased coverage" Eli Lilly's diabetes drug approved to treat heart failure Lundbeck partner soon to seek approval for new Abilify Maintena version Unvaccinated staff not welcome at Novo Nordisk's US HQ New GN device to open giant market for mild hearing loss Novo Nordisk expects to cover demand for obesity drug in 2022Coloplast drops prior skepticism, agrees to divulge national tax informationGN Hearing eyes opportunities for new product in coming US sales channelLundbeck CEO on most controversial drug approval in recent memory: Will bring new innovationXellia's delayed factory now up and running Bavarian Nordic initiates phase II trial for Covid-19 vaccine Coloplast sets climate goals for executive bonus programColoplast CEO struggling to find good acquisition candidateEU approves Danish plan to put EUR 108m behind Bavarian Nordic's Covid-19 vaccineBavarian Nordic CEO sees massive sales potential for Covid-19 vaccine after securing state aidAGC Biologics breaks ground on USD 190m Danish factoryDelayed Danish state Covid vaccine to be trialled on humans in 2022Danish Medicines Council rejects Johnson & Johnson's psoriasis medicine: "Worse than existing standard treatment"Medtronic reports good start to fiscal yearBavarian Nordic releases more specific guidance - downgrades expectationsWS Audiology revenue and operating result increase significantlyWS Audiology continues to prioritize Signia on Veterans Affairs channelVertex spends billions on CRISPR technology in search of diabetes cureWS Audiology: Quarterly reports will improve transparencyFDA approves Ascendis' weekly growth hormoneNovo Nordisk after US delivery issues: New obesity drug launch set for H2 next year Bavarian Nordic: State gains from vaccine support capped by contractLundbeck introduces vaccine requirement for US staff Ascendis aiming to become market leaderWS Audiology reports massive growth in Europe compared to pre-pandemic levelsNew factory takes AGC Danmark to another level within the corporationAscendis ready for new hires after FDA approvalTop news from MedWatch this weekNew study provides good results for Eli Lilly and BoehringerSanofi gets positive results for eczema treatment – this time in young childrenSonion changes CEO for second time in two yearsSonion chair blames pandemic for CEO exitUK denies approval for Genmab's Darzalex comboPfizer goes head to head with Sanofi's multi-blockbuster with new study dataOrphazyme expects to lay off 100 employees this yearLeo Pharma swims against US tide by allowing unvaccinated staffOrphazyme may face class action suit from US investorsNo room for more mistakes at LundbeckBavarian Nordic reports promising results for RSV vaccine in phase II trialBavarian Nordic: RSV efforts could be "key to the promised land"Ascendis Pharma aims for USD 400m from share issueMost US employers say vaccine mandates are possible by end of yearPentax rejects Ambu's claims of head startLundbeck starts new study of tablet version of drugInvestment bank: Bavarian Nordic's RSV data reduces risk associated with important assetSobi co-founder thinks acquisition is likely after USD 8bn bid Pfizer begins phase III trial for vaccine against RSVBank skeptical about Novo Nordisk share price – requires USD 40bn a year in obesity drug salesZealand Pharma Chief Medical Officer sells shares worth USD 650,000Analysts upgrade share price targets for Bavarian after run of good newsTop news from MedWatch this weekAstrazeneca and EU settle missing vaccines caseDespite recent successes, Bavarian remains second-most shorted stock on Nasdaq CopenhagenDemant on the hunt for employees: "Even high-level people are on the phone"WS Audiology brings in VP of accounting and head of communicationsDanish government cancels vaccine production tenderBiogen takes second royalties victory in blow for Forward PharmaFujifilm's factory in Denmark generates USD 430m revenueDanish government wants to spend USD 160m on permanent research and development tax deductionEMA begins assessment of Pfizer booster application Ambu leadership under scrutiny for communication styleColoplast opens new factory in Costa RicaAscendis ready with clinical trial of another cancer drug Investors worry about Lundbeck's future, analysts remain optimisticHorizon begins phase four clinical trial of Genmab drugBavarian increases capital of USD 8.9m from selling sharesLundbeck to measure brain with microscopic camera in new partnershipColoplast axed traditional budgeting process: "It wasn't promoting growth"Sanofi's big dermatology hope fails in phase IIIAnalyst thinks RSV vaccine market could reach over USD 10bnEli Lilly and Boehringer Ingelheim's Jardiance against heart failure achieves breakthrough designation from FDANovo Nordisk's new VP of digital health to focus on internal and external innovationFormer Lundbeck CEO: Voicing public opinions isn't always prudentSwedish diabetes company raises USD 17.5m for phase III trialSanofi opines on Danish government's Bavarian contract: Single supplier would be a mistakeEli Lilly to raise millions for green initiatives Top news from MedWatch this weekDenmark sells 500,000 surplus vaccines to New ZealandNo needles in sight as Novo succeeds with new capsule technologyLundbeck CEO joins board of directors at Syros PharmaceuticalsABG hires equity analyst to cover hearing health and pharmaceutical companiesNovo Holdings sets sights on more acquisitions in hot bioindustry sectorSnipr Biome to collaborate with US cancer hospitalItalian hearing aid retailer disappoints with growth prognosisGalecto begins third phase II trialInvestment bank raises guidance for Novo Nordisk after "impressive" Wegovy launchY-mabs receives priority review status for cancer drug in ChinaOlympus survives malware attack without data lossEU to present plans for new emergency health authority on ThursdayItalian hearing aid retailer expects first OTC products in 2022Leo Pharma will not use acquisition option after candidate disappoints in phase III trialAmbu changes stance, mandates vaccines for US workers Sonova says surge of Delta cases in US hasn't affected hearing aid marketNovo Nordisk Foundation grants USD 46m to new genomics research center in BostonNovo Nordisk starts crucial trial of obesity tabletWS Audiology makes headway in green conversion of Singapore headquartersIO Biotech begins phase III trial with partner MSDNew data a boost for Johnson & Johnson and Bavarian Nordic's Ebola vaccineJefferies downgrades Genmab recommendation due to lack of short-term catalystsSnipr Biome and US cancer hospital target gut microbes in attempt to eradicate immune therapy side effectsSonova enters strategic alliance with French biotech company to treat hearing lossDemant CEO: It will take a long time to meet pent-up demandLundbeck Foundation buys stake in asset managerNew EU health authority to respond rapidly to future health threatsWS Audiology still chewing over listing of online hearing companyOticon: Covid-19 led to debates about product launchesEU Commission ends Danish HERA dreams – but could provide new opportunities for the pharmaceutical industryCEO at WSA: No clarity on EQT exit plans yetCHMP recommends nine new drugs, rejects oneNovo Holdings considers sale of Xellia PharmaceuticalsBayer collaborates with Gubra to unleash peptide potentialFDA pauses Swedish diabetes company's phase III trial plansGenmab presents "encouraging" data for cervical cancer candidateCEO at GN Hearing: Properly regulated OTC sales channel could make a differenceRoche brings new general manager to Denmark from Swiss headquartersDemant increases Veterans Affairs market share slightlyFDA gives accelerated approval to Genmab and Seagen's cervical cancer drugDanish Medicines Council refuses to approve wider usage of Biogen's muscle wasting disease treatment despite yet another price cutBritt Meelby Jensen was labeled "the biotech queen": "Unfortunately, I think it demonstrates how there are still few female top executives in Denmark"Pharmacosmos settles legal dispute with ViforAnalyst: New Genmab approval shows portfolio potential New Johnson & Johnson data show high booster shot effectivenessBank sees increasing likelihood of third Novo Nordisk upgradeEli Lilly strikes deal with EU over Covid-19 antibody treatmentAnalyst: GN should sell Hearing and bet on AudioSwedish diabetes company gets domestic green light to begin phase III trialNew Genmab/Seagen drug will cost up to USD 120,000Incyte gets green light for new eczema cream – and a warningNovo Nordisk prepares phase III trial of potential blockbuster drugAmbu gets EU approval for bronchoscopeGN rejects notion of selling Hearing division, againAmbu on EU bronchoscope approval: Makes us the most wide-ranging and dominant player on the marketEU Commision working on solution for IVDR bottlenecksNovo Nordisk turns up the heat on inlicensed Genmab drug with phase III preparationsNovo Nordisk Pharmatech makes first sales agreement in MexicoGE acquires BK Medical for USD 1.45bnSenators fear inadequate OTC regulation could harm hearing device usersNovo Nordisk creates new RNA and gene therapy unitFunding deal between Bavarian Nordic and Ministry of Health approved by Danish parliamentTop news from MedWatch this weekBK Medical will retain independence after GE acquisitionUS government threatens Novo Nordisk with fine for discount program violationsNovo Nordisk settles case of market manipulation, will pay USD 100mDemant expects medium to long-term revenue growth of 7-10 percentLundbeck hopes long-term Covid-19 effects will boost Trintellix EQT wants to stay in WS Audiology for "several years"FDA postpones decision for Pfizer's weekly growth hormone treatmentNovo Nordisk strikes deal with French Biocorp to develop add-on device for insulin penDemant joins green initiative, seeks to reduce emissions by 50 percent in 2030Union Therapeutics strikes million-dollar deal with Chinese partnerAnalyst: Chinese reforms will impact sales and earnings at Novo NordiskRoche: The US and Asia outsprint Europe in life science sectorNovo Nordisk has begun phase III trial with antibody Analyst: Eli Lilly price drop is a sign of competitive US insulin market Sanofi pivots toward boosters after Covid vaccine delaysEU countries to boost research with cautious transparencyEMA starts evaluation of Moderna's booster applicationEisai and Biogen begin application process for second Alzheimer's drugFDA approves Abbvie's preventative migraine tabletAmbu heir: "We're in it for the long haul, but I would be lying if I said I don't keep track of the share price. I check in daily"Leo Pharma expands digital trial partnership, hopes to reduce costs by 25 percentIqvia wins tender to provide laboratory system for Danish National Genome CenterEMA ramps up measures to reduce animal testingJanssen begins phase III trial of RSV vaccine for older patientsRoche dismisses Novo Nordisk as potential threat on lucrative hemophilia marketColoplast recalls urology productsEli Lilly presents positive data from tirzepatide sub-studiesLeo Pharma expects new FDA ruling for eczema treatment tralokinumab in early 2022Lundbeck wins patent case against six generic medicine producersDiagnostics giant cemented its leading role during the pandemicNovo Holdings silent on newly created company with million-dollar backingTop news from MedWatch this weekJanssen is foreign company of the year in DenmarkNovo Nordisk Foundation to boost pandemic preventionLeo Pharma expands its arsenal of arguments for Adtralza with new long-term dataEMA appoints new head of international affairsJanssen presents positive results from phase II RSV vaccine trialNobel Prize goes to US scientists for discoveries of temperature and touch receptorsInternational CEO praises Danish testing efforts for "thinking more strategically and long-term than other places"EMA approves Pfizer and Moderna Covid-19 booster shotsNovo Nordisk Foundation CEO surprised by mRNA Nobel Prize snubGN downgrades expectations for GN Hearing significantlyGN Hearing to transform activities with new head of research and developmentOrphazyme to discuss NPC rejection with FDA in mid-OctoberAnalyst surprised by GN downgrade: Significantly bigger than expectedOrphazyme no longer expects EMA decision this yearGN Hearing restructures after research and development letdownAmbu downgrades financial expectationsAmbu CEO predicts short-term shipping challenges for Core businessABG Analyst expects significant costs increase at ColoplastWHO adds Novo Nordisk insulin to essential medicine listsAnalyst on Ambu downgrade: Doesn't change investment caseWeight loss as new diabetes target could boost sales of Novo Nordisk's obesity drugAudientes gets off to a flying start with Indian preordersBoston Scientific acquires company for USD 1.75bnNew unit to bring Novo Nordisk closer to goal of using RNA and gene therapies across all treatment areasWHO recommends world's first malaria vaccine for childrenLundbeck shuts down in India Despite downgrades and stock decline, Ambu chair maintains trust in leadershipAmcham welcomes new chairwoman from Siemens HealthineersTakeda's new CEO in Denmark wants to hire more peopleNew biotech Roxiant to tackle age-related diseasesNovo Nordisk hires Queen Latifah for US marketing offensiveEllab acquires British lab companyAmbu wants electric car fleet by 2030Top news from MedWatch this weekCentral EU committee makes case for faster EU drug approval processFour firms received USD 840m for running rapid Covid-19 tests in DenmarkGlobal corporate-tax overhaul advances as 136 nations sign onEU pharma strategy could allow for shorter drug patentsLundbeck silent on shutdown of Indian operationsRhovac hires investment bank to generate interest in lead candidateDanish Covid-19 treatment approved for human trialsCopenhagen Medical hires profile from Novo Nordisk FoundationLundbeck CEO expects foundation backing for large acquisitionsNovo Nordisk hopes to stabilize Wegovy supply in early 2022Life science investor adjusts organization to stay on top of its gameGlobal challenges ahead for Ambu's dreams of electric fleetFormer Shire CEO shakes up Galderma as IPO decision loomsRhovac is open to all sale and partnership opportunitiesChief scientific officer at Johnson & Johnson set to retire this yearNovo Nordisk to spend more on acquisitions and external innovationLundbeck CEO considers stepping up marketing of VyeptiEU Commission earmarks EUR 725m to secure critical production capacityStockholm wants to become leading life science regionLife science firms warm up before Tour de France starts in DenmarkWSA group CFO resigns – interim replacement appointedApple investigating Airpods as hearing health solutionAnalyst: Potential Apple product could target GN's market segmentBank predicts double blockbuster status for Novo obesity drug next yearDemant recalls cochlear implants – will cost up to EUR 13.4m in 2021, with more consequences for 2022 Lundbeck acquires phase I-ready candidate from South Korean firmEuropean health ministers welcome EU Commission's HERA Leo Pharma chairman: "In the long term, we will probably have fewer employees"Demant CEO on implant recall and sales halt: "This is very serious"New Lundbeck candidate to kick off R&D divisionFormer FDA head to make comeback under Biden, media reportsMedicon Valley chair says Swedish growth ambitions will improve Danish life scienceDenmark donates 250,000 Covid-19 vaccines to RwandaLundbeck's schizophrenia treatment for teenagers receives FDA priority review statusNovo Nordisk has picked second RNA drug candidate for USD 358m collaborationColoplast heir reaps record USD 780m profits on personal investmentsAscendis launches growth hormone Skytrofa in the US CHMP recommends six new drugsTop news from MedWatch this weekCHMP gives positive opinion on Genmab partner's lung cancer drugUnique ownership structure makes CFO position at WSA appealing and challengingBiogen stumbles in crucial ALS studyAustralian hearing aid firm starts clinical trial of affordable hearing product – will seek FDA approval in 2022French biotech firm surprises analysts with corona vaccine dataIO Biotech prepares for IPO in the USSonova acquisition to drag out into 2022Novartis subsidiary Sandoz's antibiotics efforts bear fruit during pandemicConde-Knape makes the future of pharmaceuticals possible at Novo NordiskSaniona clears obstacle ahead of new trialGenmab sales of Darzalex exceed expectations in Q3Vertex has initial success in new diabetes projectAnalyst: Darzalex sales figures could result in Genmab upgradeAnalysts say Darzalex sales prognosis could be too cautiousFDA proposes regulation for OTC hearing aids after string of delaysAnalyst on FDA proposal: Ball is in hearing aid industry's courtRoche soars in Q3, carried by Covid-19 test demandDiabetes company brings European phase III trial forward as US troubles continueBiogen Q3 results better than expected, updrades guidanceHearing aid manufacturers unconcerned about potential OTC disruptionsBiogen to apply for approval for antidepressant in 2022Audientes accelerates preparations for US market entry after OTC market newsLundbeck Foundation wants stronger biotech businesses in Denmark, but this doesn't rule out international growthGN and Demant slightly increase Veteran Affairs foothold Audientes fulfills 2021 resolution to make third Indian partnershipEMA to investigate Covid-19 treatmentLeo Pharma strongly criticizes Danish Medicines CouncilWhile others divest, Sandoz expands: "Antibiotics are the backbone of modern medicine"Sofinnova raises EUR 472m for life science fundNew Sanofi study is yet another win for blockbuster drugUS court orders Eli Lilly to pay royalties on diabetes drugsDiabetes firm Vtv Therapeutics announces new CEOTop news from MedWatch this weekResearchers find reported HPV vaccine side effects could have been due to everyday infectionsChemical leak at Novo Nordisk causes road blocksDanish regions launch ultrasound scanner tenderUnion Therapeutics starts phase II trial of nasal spray for Covid-19 patientsLeo Pharma's eczema drug for adolescents meets phase III trial targetsNovo Nordisk chemical leak under control – production unaffectedMSD provides blockbuster drug free of charge for Evaxion's combination trialLundbeck chairman demands change: "We can't live with this"Novartis beats expectations for third quarterColoplast could win big on Polish reimbursement changesDelta variant outbreaks in the US affect Össur salesAnalyst: Novartis's Kesimpta sales exceeded expectationsCloud computing saves money and cuts carbon emissions at Novo NordiskEli Lilly upgrades earnings per share guidanceSeveral positive elements in Eli Lilly Q3 report, says analystStallergenes Greer enters partnership to develop device and appInvestors' focus will be on GN Hearing's downgrade, says analyst ahead of Q3 reportUS-based obesity firm hires former Novo VPAmplifon tops sales expectationsBoston Scientific boosts endoscope sales by 11 percentDeborah Dunsire after three years at Lundbeck: "We're coming up to an inflection point in neuroscience"Bristol Myers Squibb reports double-digit growth in Q3Sanofi upgrades 2021 guidance once again – Dupixent drives growthGN launches hands-free calling for Resound One users using Apple devicesTakeda boosts sales of Lundbeck-developed drug in H1 2021Biomarin is still expecting an EMA decision on hemophilia drug in H1 2022Biomarin: Interest in new dwarfism drug for children exceeds expectationsGitte Aabo nominated for Danish leadership awardFew weeks after downgrade: GN Hearing maintains guidanceDelayed GN Hearing device sent for FDA evaluationConvatec upgrades 2021 sales forecastGN CEO on job security: "It's a board decision"WSA acquires majority of Chinese online retailerEMA gains more power to monitor medicinesAnalyst ahead of Coloplast full-year report: Focus will be 2021/22 guidanceNovo Nordisk upgrades guidanceGN Hearing's CEO regards new OTC regulation positivelyAnalyst: Unexpected Novo upgrade "demonstrates positive development"Covid-19 impact lasting longer than expected on some markets, says GN Hearing CEOLundbeck presents positive results from migraine drug trialColoplast expects organic growth of 7 percent next yearOrphazyme after FDA meeting: New phase II/III trial won't be necessaryColoplast has increased investment in company behind vapor therapyCEO wants to make Bavarian Nordic one of the world's largest vaccine companiesDemant upgrades financial guidance again despite October's implant issuesDeborah Dunsire is breaking an old pattern: The definition of madness is doing the same thing over and over, expecting a different outcomeColoplast's urology business takes growth leap after Covid-19 diveNovo CEO: The pandemic has increased the value of collaborations and dealsZealand Pharma sends obesity candidate to clinicSeasoned Lundbeck researcher poached by up-and-coming biotech firm to lead R&DDemant wins market shares: "We are a far bigger business now than before Covid-19"Novo's obesity business and Chinese challenges will be examined closely, says analystNovo Nordisk Q3 profit surpasses USD 1.8bnNovo Nordisk's biopharm arm recedes in Q3Year-to-date obesity drug sales at Novo Nordisk surpass all of 2020Coloplast prepares big study of main asset from million-dollar acquisitionObesity drug submitted for approval in Japan, Novo Nordisk reportsSemaglutide fails in phase II trial within fatty liver diseaseChinese authorities approve seasoned Novo Nordisk combination treatmentNovo Nordisk CEO encouraged by Saxenda's role in obesity business growthHorizon's Genmab drug gets blockbuster status Roche gifts blockbuster cancer drug to Galecto for new clinical partnership trialFDA fast tracks former Leo Pharma eczema candidateDiscontent with GN Hearing CEO Gitte Aabo is growing, reports mediaGN ramps up climate efforts and joins Science Based Targets initiativeNew study reveals "enormous medical value" of Lundbeck's new migraine drug compared to generics, Head of R&D saysLeo Pharma loses US region CEO – interim replacement found in current CFORaising ambitions at Novo Nordisk an obvious move, says CEOOrphazyme prepares for USD 50m capital hunt after nightmare yearGenmab upgrades financial guidance againFormer Leo Pharma candidate heads into big study as FDA fast-tracks assessmentOlympus upgrades after Covid-19 recoveryAnalyst: All of the building blocks for Genmab's upgrade were in placeColoplast CEO looks forward to pivotal launchLundbeck ready to take Genmab antibody to phase IIZealand Pharma enters US partnership over pump systemWegovy weight loss results "very encouraging," says Novo EVPNovo Nordisk waves goodbye to VP in charge of device developmentColoplast CEO wants to increase US market share to global levelColoplast acquires Atos Medical for USD 2.5bnNovo EVP says new data shows Wegovy stands out in obesity crowdAnalyst says acquisition strengthens Coloplast's core competenciesSwiss media reports of defective Sonova cochlear implantsColoplast's USD 2.5bn acquisition is its biggest everAfter historic acquisition, Coloplast CEO takes stock: "Building up capacity will take a while"Analyst will focus on Ambu's new financial guidance after preliminary Q4 figures1000 Coloplast employees to give Atos flying start in ChinaAmbu's expectations for the new financial year disappoint analystsAnalysts predict results in upper end of Lundbeck's expectations ahead of financial reportAmbu prepares wide-ranging launch of improved single-use duodenoscope Missed targets cut salaries in half for top Ambu execsAmbu plagued by transportation troubles in disappointing year – CEO has a card up his sleeveAnalyst: Duodenoscope study is a ray of sunshine on a cloudy day for AmbuAmbu has replaced its duodenoscopes the world over: "We have the product of choice"Sales of migraine drug exceed expectations at Lundbeck during third quarterNovo Nordisk objects to proposed reimbursement change for its fast-acting insulin in DenmarkLundbeck lets 300 employees go: "We are on a constant hunt to make our organization as effective as possible"Express Scripts to cover psoriasis cream from MC2 TherapeuticsNew trial of Genmab substance is symptomatic of Deborah Dunsire's LundbeckDoctors are diagnosing more patients as US market normalizes, says Lundbeck CEOAnalyst: Undramatic Lundbeck report shows fine growth for key productsNovo Nordisk to introduce vaccine mandate at US facilities from Dec. 8Genmab increases income in Q3 and maintains upgraded full-year guidanceALK upgrades guidance after positive Q3 reportGenmab CEO says lower operating costs are a fleeting phenomenon Dropping two drug candidates puts Genmab in a better position, says CEOFocus will be on vaccine sales and pipeline news when Bavarian Nordic report is released, says bankGenmab is considering Covid-19 testing mandate for employees – if guidelines allowGlobal supply issues have ALK thinking creatively Ascendis Pharma doubles sales expenses ahead of product launchPfizer acquires commercial rights to Biohaven migraine drug outside the USZealand Pharma downgrades after disappointing Zegalogue salesNovo Nordisk within touching distance of European obesity market as CHMP recommends approvalEuropean interest in Wegovy expected to match US demand, says EVP at Novo NordiskBavarian Nordic CEO receives "extraordinary" retention bonusPositive CHMP opinion paves way for Lundbeck's Vyepti in EuropeCovid-19 has potentially cost Bavarian Nordic EUR 100mCHMP recommends higher dose of Novo Nordisk's OzempicNovo Nordisk creates AI division to help novel drug developmentCHMP vouches for Ascendis Pharma's growth hormone for childrenCHMP approves 11 new drugs, rejects oneEli Lilly and Boehringer drug gets head start at FDASonova beats expectations, lands USD 1.74bn revenueLeo Pharma refinances loans and links costs to sustainability targetsLundbeck begins phase II trial of antibody for migraine prevention Danish politicians furious over "deeply provocative" Bavarian bonusALK CEO on peanut allergy competitors: "They might have been the first, but that does not necessarily mean they are the best"ALK still has two horses in adrenaline raceBiotech company closes heavily oversubscribed financing roundAudientes enters into fourth Indian partnership – now spans 90 retail locationsSingle-use scopes take center stage at Ambu as core business areas recedeLeo Pharma starts phase II trial of Korean tabletAnalyst predicts blockbuster potential for Biomarin's growth hormoneALK execs sell shares worth USD 4mZealand Pharma CEO undeterred by lower than expected Zegalogue salesGE to capitalize on increasing demand for diagnosticsSiemens Healthineers upgrades mid-term guidanceCEO of Pila Pharma increases share holding to over a thirdImpact of China's drug policy will be visible soon, says JefferiesColumn: The EU must up its game to retain pharma strengthBiogen's Alzheimer's drug Aduhelm faces EU rejectionPharmacosmos sees big potential in million-dollar acquisitionEMA begins review of Novavax's Covid-19 vaccineInternational antibiotics resistance organization ICARS gains independenceGN Hearing's devices approved in the EU, granted CE markingNovo Nordisk acquires Dicerna for USD 3.3bnNew EU directive to require enormous cybersecurity investmentsLikely EU rejection of Biogen's Alzheimer's drug comes as no surprise, says dementia researcherHuge acquisition scores Novo Nordisk an FDA-ready treatmentNovo Nordisk will take Dicerna's technology to the next level, says EVPEli Lilly reaps rewards of Novo acquisitionJanssen sees USD 12bn sales potential in Genmab-developed drugsAscendis presents data from phase II trial of rare hormone disease treatmentCompetitors turned collaborators: Dicerna acquisition sends Novo Nordisk into the arms of rivals Eli Lilly and Boehringer IngelheimBiogen's EU setback highlights importance of research, says Alzheimer's organizationAmbu's new duodenoscope reaches over 98 percent success rateBiomarin's dwarfism drug receives FDA approvalEMA allows emergency use of MSD's Covid-19 capsule treatmentAnalyst: Positive results from Ambu's Duodeno 1.5 reflected in Ambu sharesSonova loses Veterans Affairs market sharesZealand Pharma reports positive data from phase Ib trialLundbeck Foundation portfolio company acquired for USD 230mRaw materials price spikes will prove costly for the life science industryGrass allergy sufferers wanted for Lundbeck phase I antibody studyNovo Nordisk Foundation's CEO warns antibiotic resistance will be world's second-biggest killerAnthony Mancini will help Genmab take its next stepsJoe Biden hopes to end "outrageous" insulin pricesAmbu introduces corona passport requirement in DenmarkNykode Therapeutics CEO after another million-dollar deal: We have no competitorsNovo Nordisk's reimbursement appeal goes unheard, Sanofi insulin deemed equivalentDicerna CEO explains how a desire to expand collaborations turned into a potential acquisitionAnalyst on Novo stock: The risk of disappointments is bigger than the chance of surprisesEargo faces delisting if it fails to provide Q3 reportEuropean pharma strategy report approved with huge majority Dicerna expects to continue collaborating with Novo's rivals after potential acquisitionNovo Nordisk Pharmatech and Novozymes enter into enzyme partnershipDicerna pushed up price and contacted other suitors before making deal with Novo NordiskDanish tax authority wins million-dollar legal dispute – Supreme Court case may followEMA recommends Covid-19 vaccination for children as young as 5Novo Nordisk is making progress toward stabilizing Wegovy supplyNovo Nordisk gets obesity drug approved in CanadaNovo Nordisk's sales growth will be negatively impacted in 2022Analyst: Novo Nordisk's estimated sales growth decrease not as big as expectedWHO calls in experts to assess new Covid-19 variantTop news from MedWatch this weekProfessor says vaccines can easily be modeled after new Covid-19 variantsFunding deal secures Denmark first batches of Bavarian Nordic's Covid-19 vaccinePharmaceutical giants prepare for battle with new corona variantMSD Covid-19 treatment less effective than first thoughtColumn: The EU pharma strategy must become more ambitiousNovo Holdings board member steps down after less than two years in roleAmbu board member sells 5,000 sharesBavarian Nordic: We can adapt our vaccine if necessaryLundbeck appoints new chief commercial officerNew plan for insulin reimbursement concerns Danish diabetes associationDenmark has the cheapest generic medicines in Europe, study findsPresident and CEO of Leo Pharma to resignEU countries approve new powers for disease prevention agencyEU drugs agency can clear Omicron shot in 4 months if neededColoplast starts testing sensor-based product for ostomy leakageLeo Pharma looks for CEO with capital markets experience ahead of IPOGenmab pipeline hype makes investment bank uneasyHeadhunter calls outgoing Leo Pharma CEO a "flop"European reference laboratory network to ensure better data across the regionDanish Medicines Council could be a roadblock for sclerosis drug KesimptaPresident of the European Commission puts mandatory vaccination on the table"Real world" patient data documents the long-term effects of ALK vaccinesContact with consumers will secure continued growth in China, says SonovaCSL eyeing acquisition candidate in Vifor PharmaY-mabs CEO has big ambitions: Wants to create the Tesla of biotechAGC's Japanese and Danish factories to produce German biotech firm's drug candidateEMA begins rolling review of another Covid-19 vaccineFDA approves another Darzalex combination treatmentA.P. Moller Holding set to acquire UnilabsNovo Nordisk wins big on strong US dollarBillion-dollar acquisition of Sobi failsLundbeck has great expectations for new antibody: "This could be the new generation of migraine drugs"Astra sinks Advent's USD 7.6bn buyout of biotech SobiTop news from MedWatch this weekPhase II study confirms efficacy of Bavarian Nordic's Covid-19 vaccineLeo Pharma sells development program, becomes shareholder of Swedish biotech buyerBavarian plans to send RSV vaccine to phase III, prepares equity raiseA.P. Moller Holding rejects future life science investments despite record-breaking purchaseAmbu wins single-use endoscope contract with US healthcare service giantBavarian Nordic EVP on Covid-19 vaccine: "We couldn't have wished for better data"Lundbeck Head of R&D denies allergy aspirationsAudientes enters fifth partnership in India, extends reach into populous rural areasBavarian Nordic finds buyers for accelerated share offeringIO Biotech expands collaboration with MSD – begins phase II trialNovo's acquisition has legal ramifications: Dicerna sued by shareholdersSonova to sell Australian-developed hearing aidsLundbeck's chief financial officer to exit before May 2022EU Council recommends extending deadline for implementing new cybersecurity law Lundbeck's CEO: Departing CFO is not defecting to competitorGN chair promises delayed product launches in H1 2022Lundbeck's former head of North America appointed CEO of Capsida BiotherapeuticsGN chair puts no blame on GN Hearing's CEO Gitte AaboLundbeck's CFO of 14 years to join VeluxGN Hearing loses Veterans Affairs market shares in NovemberUS-based biotech firm fires two-thirds of employees, focuses on diabetesDicerna on Novo's billion-dollar acquisition: Alleged wrongdoing has no hold in realityScandalized hearing firm Eargo fires one fourth of employeesWSA lost EUR 81.9m during 2021Orphazyme makes changes to board of directorsColoplast's new country-by-country tax report reveals enormous national differencesAlmost three years after the merger of Widex and Sivantos, WSA enters a new phaseBig Bavarian Nordic shareholder on pivotal projects: "We're in a completely unique position"EMA: Omicron cases appear "mostly mild"Novozymes closes majority stake acquisition of SynergiaSynact Pharma intensifies partnership discussionsBavarian Nordic's spending on factory expansion exceeds USD 150mUS trade agency extends deadline of Novo Nordisk's historic acquisition Copenhagen lands top three spot in global pharmaceutical rankingEli Lilly enters into strategic partnership on metabolic diseases with Regor TherapeuticsNovo Nordisk invests USD 2.6bn in new manufacturing facilitiesColoplast moves important production to country on tax haven watch listGenmab partner receives conditional EU approval for cancer drugContinued growth expectations behind Novo Nordisk's biggest ever manufacturing investmentEli Lilly enters into USD 300m research partnership with Foghorn Therapeutics Questions about Demant's future remain as 2022 nearsGN Hearing acquires US-based online marketing platform for USD 94.8mNGO slams "hypocritical" Coloplast for keeping Costa Rica accounts secretLeo Pharma begins phase IIb study of oral atopic dermatitis drugAnalyst says GN Hearing's acquisition will build bridges and bring in customers Novo still expecting EU Wegovy approval around the New YearGN Hearing left 9 percent ownership in Lively's hands to ensure work motivationZealand Pharma enters USD 200m financing agreement Novo CEO is on the hunt for future growth: "The pressure is bigger than ever"Genmab raises USD 2.4m from employee warrant exerciseGE Healthcare partners up with Minerva on precision medicineZealand Pharma may use acquisition option to beef up commercial muscle, CEO saysEli Lilly upgrades revenue and earnings per share expectationsCEO of Novo Nordisk on potential successors: "I've only just begun"MEP seeks to add Bavarian Nordic to vaccine contract court caseZealand Pharma ends recruitment for phase III study of glepaglutideDicerna CEO fears insider trading crackdown, withdraws own shares from Novo Nordisk offerEli Lilly submits tirzepatide for approval in US and EUDenmark allows unapproved pill for at-risk Covid-19 patients in line with EMA adviceDanish life science exports nearly tripled in 12 years: "We have yet to reach our goal"Novo CEO on US obesity drug demand: "It was the perfect storm"Nykode Therapeutics proposes chair of Zealand Pharma to lead own boardNovo Nordisk Foundation grants EUR 300m to new research centerDoctors doubt effect of new Covid-19 tablet EMA provides guidelines for another unauthorized Covid-19 tabletBiogen's Aduhelm rejected by EMA committeeCHMP approves 13 new drugsUS manufacturer cannot supply Wegovy injector pen syringesDemant identifies cochlear implant fault, plans market return in late 2022Novo Nordisk on problems at contract manufacturer: "They need time"Biogen slashes price of controversial Alzheimer's drugCompanies celebrate new stem cell center as an alliance and recruitment catalystNovo Nordisk must stay ready to increase Wegovy sales, says CFONovo Seeds invests in Dutch biotech firm with NASH focus againFDA expands indication for Amgen psoriasis drugLundbeck broadens phase III trial of Vyepti in childrenLundbeck finds new head of clinical developmentAmbu recalls resuscitation product Roche General Manager talks teamwork, international networking and Danish neighborsGradual IVDR implementation backed by EUFDA rejects Takeda/Shire candidateDanish firm launches cryotherapy venture in US following FDA approvalPension companies push for Coloplast's secret Costa Rica tax reportWSA appoints new CFOBiogen's Alzheimer's drug blocked in JapanBavarian's biggest competitors have a landmark 2022 aheadKaro Pharma acquires Reckitt's dermatology brand E4Analytics firm predicts global psoriasis market to grow twofold by 2030Big investments in Danish life science industry make 2021 historic year for raising capitalEditor in chief blasts Facebook following censure of Pfizer-critical articleHigh growth at low margins is better than the reverse, says Novo Nordisk CEODenmark defends controversial Covid-19 pillFDA approves Leo Pharma's tralokinumab after rejection 8 months agoLeo Pharma's US sales organization waited 8 months on approval: "It has had an economic impact"Novo Nordisk closes Dicerna acquisition dealNovo Nordisk predicts period of "different" growth when semaglutide patents expireAnalyst: Novo Nordisk was expected to complete acquisition – despite issues Nykode initiates clinical study of "pan-variant" Covid-19 vaccine Director at Lundbeck: "Some whistleblowers write in a way that makes it completely impossible to investigate anything at all"Allarity considers partnerships for the potential launch of cancer drugJanssen applies for FDA approval for Genmab drugAudientes strengthens leadership team with industry veteranSanofi loses bid to revive Lantus Solostar insulin-pen patentsThis year's most read stories from MedWatchDrug commercialization company Medical Knowledge Group acquired by Novo HoldingsAscendis Pharma extends trial of growth hormone in adults EQT reinforces long-term nature of WS Audiology investmentNovo Holdings acquisition highlights growing pharma commercialization service market, says managing partnerWS Audiology acquires Brazilian distributorAnalyst to focus on Bavarian Nordic, Novo Nordisk and Lundbeck in 2022Former Lundbeck venture advisors start new biotech fund"Bad luck" delayed Leo Pharma's prize candidate for eight monthsNovo Holdings acquires US contract manufacturer in second billion-dollar deal in two daysUnion Therapeutics recruits first psoriasis patient for phase IIb studyGenmab buys ADC technology license from SynaffixA.P. Moller Holding invests USD 50.8m in Blue Ocean Robotics2curex finds partner for Polish launchFDA fast-tracks Abbvie's lung cancer drugBiotech boss overjoyed by new life science fund: "The more the merrier"Former Alnylam CEO appointed new chair of HemabNovo Nordisk trains sights on Roche with "aggressive" hemophilia drug developmentSet-in-stone criteria will reduce risk for new biotech fundPharmacosmos investigates anemia treatment in new patient groupAmbu launches two new endoscope cartsNovo Nordisk expects lack of Wegovy doses to continue until H2 2022Novo Nordisk expands research collaboration to develop hemophilia drugFDA approves Lundbeck's schizophrenia treatment for teenagersColoplast disappoints pension firm: "The outcome doesn't please the company, the investors or the employees"Amgen combines Danish and Norwegian unitsChildren's pain relief company wants former Genmab boss on boardFormer Symphogen colleagues reunited in Norwegian biotech companyTop news from MedWatch this weekNovo Nordisk CEO spies new pharmaceutical sales modelPension firm: Coloplast's secret tax report could cost skilled employees Catalent behind Novo Nordisk's supply issues, says mediaBiomarin's hemophilia drug meets all endpoints in phase III studyAmgen to free up time and capacity with new Danish-Norwegian management teamEstron's CEO steps down – hunt for replacement has begunEuropean Biomedical Alliance appoints Danish presidentSnipr Biome to send first candidate to clinicGates Foundation awards women's health grant to life science incubator firm – new CIO hiredDanish notified body expected approved in 2023Olympus designates three focus areas for its endoscopy businessBiogen's Alzheimer's drug loses subsidies in the USDementia professor "humbled, proud and honored" to take on Biomedical Alliance's president roleAudientes starts 2022 with another Indian partnershipNovo Holdings participates in USD 100m financing round of Chinese contractorBioinnovation Institute wants to boost women's health research: "It hasn't been prestigious enough"EU Commission to consider medtech industry's recruitment challengesBioinnovation Institute reaches DKK 1bn milestoneNovo Group employees raise USD 3.5m to fight Covid-19Lawyer leaves Novo Nordisk, joins LundbeckEli Lilly considers copying Novo Nordisk's semaglutide branding strategyDemant gets FDA green light for new bone-anchored hearing solutionLeo Pharma and Astrazeneca keep future plans tight for tralokinumabAscendis Pharma's growth hormone formally approved in the EUSonova acquires US-based hearing aid provider for USD 310mGenmab CEO hopes for verdict in Johnson & Johnson arbitration soonNovo Holdings lets billions of dollars flow, bets big on Chinese and US acquisitionsAscendis to investigate new indications following EU approval17 notified bodies have filed for IVDR designationTen EMA initiatives will strengthen clinical research in EuropeTop news from MedWatch this weekNovo Nordisk settles securities lawsuit in DenmarkSnipr Biome chose clinical debut in CRISPR-ready USAAn end to lawsuit is positive for Novo Nordisk, says analystLeo Pharma closely followed by Pfizer and Abbvie with FDA atopic eczema approvalsAnalyst: GN price drop is an obvious opportunity to buyStallergenes bets big on personalized allergy treatment, enters another research collaborationNovo Holdings participates in USD 150m financing round of digital health companyBioinnovation Institute ramps up ambitions, wants twice as many companies under its wingLeo Pharma and Roche want to strengthen clinical research in DenmarkColoplast chair on transparent tax payments: "Experiences aren't especially good"Sonova wins Veterans Affairs market shares in DecemberOrphazyme upgrades after careful spending yearBavarian Nordic brings in chief operating officer from GSK VaccinesNovo Nordisk partners with Swiss biotech firm on obesity – zebrafish to unlock new drugsGN enters partnership to detect cognitive impairment in people with hearing lossLayoffs and restructuring will prepare Leo Pharma for IPOWSA merges with its independent retailerLeo Pharma ends Boston betHearing aid industry association responds to FDA's proposed OTC regulationOverwhelming majority passes new EMA powersSwedish bank slashes Novo Nordisk price target ahead of 2022 outlookDanish bank expects slow start to 2022 for Coloplast, lowers price targetLeo Pharma's Boston boss exits companyZealand Pharma finds all patients for phase III studyNovo Nordisk launches oral semaglutide in IndiaColoplast initiates trial of ostomy leakage product Audientes ships first hearing aid batch to IndiaDanish bank cuts Genmab price target, retains "buy" recommendationHearing firms urge FDA to increase OTC safety requirementsTop news from MedWatch this weekAnalyst suggests Coloplast could utilize currency fluctuations in potential upgradeNovo Nordisk spotlights star diabetes drugs in massive TV ad campaignsLundbeck receives grant from Michael J. Fox Foundation in hunt for Parkinson's testFDA rejects Pfizer's weekly growth hormoneSymphogen turns year-long deficits into first profitable year following Servier acquisitionLundbeck's migraine drug approved in EUNew CCO at crisis-hit Lundbeck: "2022 will be a growth year for Lundbeck in all regions"Demant's surgical division loses president of 13 yearsColoplast upgrades growth expectations following acquisitionGenmab: Darzalex sales in line with expectationsHearing aid market in US grew by 37 percent in 2021FDA fast-tracks Snipr Biome's primary candidateAs raw material and energy prices rise, so do Coloplast's costs Orphazyme seeks shareholder support in future capital raiseAnalyst on Coloplast: Very good financial report was helped by favorable currency ratesDanish bank changes Coloplast recommendation to "buy"Snipr Biome CEO delighted over FDA fast-track statusPatients are returning in Europe, but China and US lag behind, says Coloplast's CEOBavarian Nordic and other vaccine companies suffer as Covid-19 restrictions ease: "You might ask whether the ship has sailed"Amnesty warns Danish firms at Dubai health event: ”Do your due diligence”Starkey calls out President Biden: Hearing aids aren't consumer electronicsAllergy Therapeutics cleared by FDA to start testing peanut allergy vaccine Danish researchers working on vaccine for multiple cancersCHMP recommends approval of Pfizer's Covid-19 pillDanish Medicines Council recommends Genmab-developed sclerosis drugTen firms win second joint Nordic medicine tenderLeo Pharma files for marketing approval of tralokinumab in JapanNew EU portal for clinical trials launches on MondayCHMP approves seven new drugsTop news from MedWatch this weekEli Lilly to build USD 1bn factory in North CarolinaNovo Nordisk and Eli Lilly ramped up lobbying efforts when US legislators targeted insulin pricesBavarian aims for universal Covid-19 boosterDanish bank eyes uncertainties for Demant in 2022Eli Lilly prepares for FDA rejection of eczema treatmentDanish chamber of commerce says notified body should be followed up by reference labBritt Meelby Jensen steps down as CEO of Atos Medical Leo Pharma poaches Orphazyme CEOProduction issues could put a damper on Novo Nordisk's 2022Novo Nordisk to expand insulin pen recycling campaign to more countriesÖssur driven by growth in EMEA and APAC regions in Q4AJ Vaccines brings in former Lundbeck exec as new CEOAll eyes on Novo's new outlook on eve of 2021 reportNovo Nordisk had a record-breaking 2021 profit, but has reined in expectations for 2022Novo Nordisk aims higher than analysts in 2022 outlookObesity business grows at Novo Nordisk despite Wegovy woesNovartis increases sales of Genmab-developed sclerosis drugDisappointing phase I results halt Novo's Dutch acquisitionBiopharma sales slightly lower than expected at Novo NordiskNovo Nordisk plans to submit weekly growth hormone for approval in H1Novo Nordisk invests billions of dollars in post-semaglutide futureNovo CEO: Obesity goal within touching distance well before 2025 deadlineNovo CEO calls Wegovy problems "a perfect storm," will not move production in-houseLeo Pharma sells app firmNovo Nordisk spies great hemophilia opportunities with partner GenmabNovo Nordisk stops development of new insulin product Novo Nordisk ready to go toe to toe with AscendisEli Lilly's Trulicity beats growth expectationsBoston Scientific's endoscope business grows by over 20 percentEli Lilly under pressure as Alzheimer's application delayedLeo Innovation Lab says sale of spinoff is "stamp of approval"Ambu's Ascope Gastro and Abox 2 approved by FDANovo development exec: ”I’m looking at a rich pipeline across all therapy areas"Sanofi sees higher earnings as blockbuster skin drug soarsLeo Pharma introduces bonus program for employeesNovo CEO eyes cheap biotech market: "Of course the price matters, but there are other factors, too"Olympus increases endoscopy sales, monitors supply chain issuesTop news from MedWatch this weekAbbvie to submit first Genmab collaboration candidate in 2022Genetic researchers map different migraine types in hunt for new treatmentNovo Nordisk execs sell out after receiving sharesDemant unveils parts of full-year report by mistakeGN Hearing expands flagship portfolio with new product Janssen submits Genmab-developed drug for EMA approval Demant's 2022 growth prognosis to take center stage in full-year report after accidental releaseLogistics and comparisons will bring growth down for Ambu, analyst saysAnalyst ahead of ALK report: Focus will be on 2022 prognosis Demant reports record operating resultAmbu beats expectations but sees considerable setbacks compared to last yearALK predicts 8–12 percent revenue growth in 2022Bank says Demant prognosis probably affected by component shortagesCEO of GN Hearing: R&D is back under control after restructuringEMA updates Spinraza's product summary, gives Biogen hope in DenmarkDemant sees window of opportunity as millions lack hearing aids due to Covid-19Ambu's CEO remains confident of job security despite run of bad newsGN announces US launch of hybrid hearing aid built for OTC salesLundbeck eyes progress in 2022, disappoints compared to consensusAnalyst on Ambu report: Mixed results but still thumbs-downGN Hearing: We are uniquely positioned in the OTC channelALK maintains China bet despite geopolitical unrestDemant and Sonova take Veterans Affairs market shares in JanuaryNew product will positively impact sales prognosis, says CEO at GN HearingNovo Nordisk could lose millions on discount dispute in USLundbeck's Northera took massive dive in 2021GN Hearing will grow by 5–10 percent in 2022WS Audiology's revenue grows by 10 percent in Q1Deborah Dunsire aims for 10 European Vyepti launches this yearMajority owner: Lundbeck's new share structure could double acquisition powerWS Audiology looks to new OTC market – but won't disclose plansGN Hearing will prepare for continued logistical issues with million-dollar injectionDeborah Dunsire beats Novo Nordisk CEO in salary comparisonOrphazyme plans to resubmit FDA application in H2CEO of WSA: Broad product portfolio behind Q1 growthComponent shortages impact WSAGN Hearing CEO takes pay cut due to downgrade and launch problems HERA launches first work plan with millions in R&D financingLeo Pharma to test tralokinumab with new device in phase III studyTop news from MedWatch this weekLundbeck preps for war against generic drugmakers in USBavarian Nordic receives special designation from FDAEli Lilly warms up for summer launch with long-term success goalUpcoming hearing aid will be GN Hearing's last under Resound One brandFrom zero to hero – the rise of Novo Nordisk's best-selling drugALK bets on well-known tablet technology to treat peanut allergyBlackrock increases Novo Nordisk holding to over 5 percent Novo Nordisk sues Teva over generic drug developmentZealand Pharma finishes phase III enrollmentBavarian Nordic on FDA special status: A huge validationLong-standing GN board member steps downAnalyst ahead of Genmab report: Focus will be on Darzalex prognosis Denmark responds after Covid-19 numbers used in scare tacticOrphazyme gets investor backing for fundraising roundUS Senate confirms Biden's FDA candidateHearing firm Med-El launches historic first implant for younger children Blow for Eli Lilly as research institute deems diabetes candidate no better than competitionDanish scientists first in Europe to use new clinical trial databaseDanish cases drop, defying critics of early end to Covid curbsNovo's antibiotic fund participates in financing round of infectious diseases firm Genmab raises 2022 sales outlook to top USD 1.6bnGenmab CEO: Tivdak launch has provided important experience for future treatmentsOrphazyme elects new board member Genmab CEO hopes arbitration uncertainties will ease off soon Prominent investors criticize Lundbeck's share structure splitGenmab CFO targets 39-percent recurring revenue growth in 2022 Employee growth to continue as Genmab offices specialize across the globeLeo Pharma poaches Novo Nordisk VP to lead US divisionGenmab CEO lands USD 6.8m salary in 2021Moderna plans to open office in DenmarkGenmab CEO expects more legal twists in futureGlaxosmithkline halts RSV trial after safety recommendation Orifarm ramps up growth plans following USD 703m acquisition Novo Nordisk participates in USD 57m financing round at strategic partnerAlmirall launches MC2 Therapeutics-developed psoriasis cream in EuropeGenmab CEO eyes big opportunities in global biotech downswingColoplast starts share buyback programFDA rejects Allarity's cancer candidate, demands more dataChairman intends to retire from Almirall in MayFinnish investor looks for Nordic investors in its new life science & health fundAlmirall's psoriasis drug drives 2021 growth ahead of duller 2022 outlookNovo Nordisk proposes new vice chair and board memberLeo Pharma owner: "You can’t go public without a growth outlook or an interesting pipeline"Leo Pharma to terminate up to 150 R&D jobsALK proposes to split shares into 20Novo Holdings appoints new CFOMedia changes Lundbeck recommendation to "buy"Smith & Nephew releases full-year report, appoints new CEOHovione enters partnership with Zerion Pharma Sunstone participates in EUR 39m financing round of Targed BiopharmaALK CEO misses bonus target for fifth year in a rowModerna initiates phase III study of RSV vaccineOrphazyme to give oral explanation as EMA committee decision nearsMillion-dollar investment from Eir Ventures will bring Swedish cancer company to clinicBavarian unconcerned by Moderna RSV advance: ”It's completely as expected"Novo Nordisk enters 8-year long partnership with sustainable aviation fuel firmOrphazyme predicts EU rejection after meeting with CHMPAbbvie seeks to add major depressive disorder to drug labelNovo Nordisk slams Danish Medicines Council's methodology: Has flaws and shortcomingsOrphazyme stock plummets following bad news from CHMPNovo Nordisk restores enough Wegovy supply to meet prescriptions in US Biomarin projects 2022 Voxzogo sales of USD 115m Orphazyme deputy chair thinks layoffs could be option after EU disappointmentNovo Nordisk expects drugs excluded from sanctions against RussiaOrphazyme board member on expected EMA rejection: "The next few days will be hell"Janssen puzzled by Denmark's refusal of antidepressant nasal sprayRussian invasion of Ukraine could impact over 200 clinical studiesBrokerage firm slashes Orphazyme price target by 77 percentLundbeck maps pandemic mental health impact on US residentsCHMP approves 13 new drugsTop news from MedWatch this weekAdditional phase II data backs up Bavarian Nordic's Covid-19 vaccineOrphazyme CFO to take up CEO mantle ahead of timeWidex families on future WSA co-owners: Danish investors preferred to public listingAnalyst: Bavarian Nordic has an attractive Covid-19 vaccine candidateAudientes gets green light to sell self-fitting hearing aid in IndiaAscendis Pharma initiates clinical trial of dwarfism drugBavarian Nordic's vaccine has potential to last longer than competition, says CEO Coloplast senior vice president leaves for new roleCanon acquires Danish x-ray company NRTFuture of Novo Nordisk, Lundbeck and Ascendis Pharma trials in Ukraine remains unclearLundbeck donates USD 1.5m to Danish Red Cross for emergency relief in UkraineSonova completes Alpaca Audiology acquisitionThree years after merger, WS Audiology is stronger than everGenmab appoints two new executivesAbbvie takes over Novo Holdings portfolio company Biden wants to cut costs of prescription drugs in the USGN suspends all trading with RussiaAnalyst: Biden's insulin message won't negatively impact Novo NordiskDemant breaks off all trading with Russia after GN boycott, WSA says supplying Russia "impossible"Sonova has finished acquiring Sennheiser's consumer divisionLundbeck will supply Russia with medicine for as long as sanctions allow GN Hearing's boycott decision was a "principled stance"Pfizer's RSV candidate receives FDA special statusNovo Nordisk donates two months' worth of insulin to UkraineAnalyst: Focus on Bavarian Nordic's 2022 outlook, orders and costs in upcoming reportWegovy update on Novo Nordisk's capital markets day agendaFounder steps down from CEO role at Beta BionicsNovo Nordisk aims for three new Dicerna drug candidates a yearNovo Nordisk CEO: "We are very encouraged by growth momentum"Sonova will continue trading with RussiaAscendis continued big investments into 2021, driving operating deficit upNovo Nordisk's first phase III data for weekly insulin to be released in few monthsOrphazyme postpones 2021 annual reportNovo expects GLP-1 products to drive diabetes business growth Novo Nordisk more than doubles 2025 obesity sales goalBavarian Nordic expects revenue setback in 2022Demant buys 20 percent of Chinese firm, eyes full purchase laterChinese dispensation allows ALK to file for registrationCEO of ALK on Chinese waiver: ”Some of the best news ALK has had in years"Novo Nordisk launches smart insulin pens in the UKNew EMA powers have come into forceRussian invasion of Ukraine could have multimillion-dollar impact on Novo NordiskLeo Pharma can switch away from gas within 72 hours if neededVaccine acquisitions could pave the way for Bavarian Nordic's 2025 ambitionsUS transformation has been successful, says Novo Nordisk's country headBavarian is still open for contract production – but in-house projects come firstNovo Nordisk to focus on patient outreach, prescribing doctors and subsidies to reach obesity goalsNovo Nordisk's gilded stock yields almost USD 59bn over 20 yearsNovo Nordisk initiates patent suit to stop Ozempic copiesSmall molecules to lead Leo Pharma to greatnessConvatec expects up to 5.5 percent growth in 2022Two years after criticism: Ambu and Leo's efforts to bring more women into leadership have mixed resultsGenmab receives orphan drug designation from FDASanctions expert: Sonova's sales in Russia are still permittedSanofi and Sobi's hemophilia drug meets phase III primary endpoint Leo Pharma finds new medical director at BayerNovo CFO: Obesity market is difficult to predictPharmaceutical firms prepare for potential Russian gas haltMerck Denmark joins Novo Nordisk's injection pen recycling campaignNovo expands research collaboration with US universitiesColoplast doesn't expect impact from potential Russian gas haltAdvanced Bionics loses patent infringement suit Novo Nordisk spotlights future innovations within diabetes as insulin sales recedeLeo Pharma's board still struggles with skewed gender ratio Bavarian Nordic brings in CEO of Innovation Fund DenmarkNetwork of seven women aims to put gender equality on the life science agendaDemant expands executive board to four membersOrphazyme seeks court protection during restructuringZealand Pharma reports higher costs in 2021Orphazyme gets requested observation status CEO of WSA: "Multi channel is the future"Russian firms now allowed to violate patents from "unfriendly" countriesOrphazyme stock in free fall after in-court restructuring requestTop news from MedWatch this weekAscendis Pharma reports promising phase III dataAnalyst: Zealand Pharma pipeline will be crucialNo replacement nominated for outgoing Bavarian board memberRussian ambassador to Denmark: Takeover of foreign firms is an optionEU agrees on approach to gender equality directiveNovo Nordisk grants Taiwanese firm access to smart pen data Genmab nominates Eli Lilly veteran as board memberWHO urges Ukrainian labs to destroy pathogens as war rages onNovo Nordisk Foundation teams up with Gates Foundation: "It isn't a question of if another pandemic hits, it is a question of when"Sanofi and Blackstone enter multimillion-euro partnership on bone marrow cancer drugAmbu brings in new CFO from RocheT&W Holding's historical result due to tailwinds on the financial marketsBiogen and Eisai change agreements on Alzheimer's drugMSD stops prostate cancer trial Lack of IT specialists could hamper life science growthGilde Healthcare closes oversubscribed fundEli Lilly halts new studies and exports of some medicines to RussiaNovo Holdings participates in series B round at Belgian cancer firmSnipr Biome expands executive management teamBiogen lays out long-awaited Alzheimer’s data in obscure journalVice chair and board member leave Leo PharmaLeo Pharma disappoints as deficit surpasses USD 720m Roche tops ranking of pharmaceutical industry's 2021 R&D budgetsWS Audiology halts IPO plans for subsidiaryLeo Pharma executives receive huge bonuses despite multi-million dollar deficitEMA management board elects new chairDelayed US approval will hit Leo Pharma at full strength this yearLeo Pharma will retain thrombosis business despite goal to focus on dermatologyAnalysts sow doubts about Ambu's projections Orphazyme to convene creditors for meeting on company restructuringAmplifon lands all-time high revenue, projects positive 2022Top news from MedWatch this weekGN and Demant lost ground with veterans in FebruaryBavarian Nordic enters license agreement with Nuance Pharma on RSV candidateNovo Nordisk creates new unit to ramp up use of artificial intelligence and digital tools in researchLundbeck parks Alzheimer's drug hope as there is no evidence it worksBavarian Nordic could be first on the RSV market in ChinaBoehringer Ingelheim and Saniona schizophrenia partnership advances to next stageNovo Nordisk winds down clinical activities in RussiaAnalyst: Bavarian Nordic RSV partnership could be first of manyBavarian Nordic hunting for RSV partners: "If the firm is too small, we might as well consider launching ourselves"Orphazyme files for delisting in USNovo Nordisk recruits 500 people for Alzheimer's trial Orphazyme withdraws marketing application ahead of final voteSwedish biotech firm gets green light to take diabetes candidate to clinical phaseHeavy-handed Covid-19 approach in China causes problems for hearing aid firmsThe Lundbeck Foundation delivers record-breaking resultAmbu and Coloplast unaffected by Covid-19 lockdowns in China – for nowMedia: Lack of buyers' interest in Novo Holdings-owned Xellia Pharmaceuticals Lundbeck faces criticism over new share structureLundbeck has halted studies in Russia, continues to supply medicine Lundbeck chair on shareholder criticism: Share split benefits everyoneColoplast study demonstrates significant improvements with Provox LifeGN Hearing wants an EBITA margin of over 20 percent in 2024Leo Pharma has applied for expanded approval for eczema treatment in EUAnalyst: Obesity market could surpass USD 70bn by 2030Ascendis Pharma to raise capital with convertible notesColumn: This is how the Danish Medicines Council should strengthen its application processNovo Nordisk settles patent infringement lawsuit with NovartisNovo CEO condemns invasion of Ukraine – but keeps Russian factory runningNew vice chair elected to Novo Nordisk boardAudientes predicts top sales of USD 4m in 2022, plans capital raise Novo Nordisk chair believes in globalization despite international tensionsAscendis veteran leaves chair role at Swedish biotech firm Another win for Pfizer as RSV vaccine receives FDA special statusWS Audiology and GN settle false advertising case in US CHMP approves 5 new drugs in MarchTop news from MedWatch this weekDemant to release quarterly figures from May onwards Danish Medicines Council releases recommendations – mixed bag for Sanofi and BMSNovo Nordisk's acquisition journey is driven by price pressure and a hunger for innovationGN denies involvement in false advertising caseNovo Holdings beats record as value of assets exceeds EUR 90bnJapan approves iron deficiency drug from PharmacosmosPotential success could be head-scratcher for Novo Nordisk chairNovo Nordisk gets 2.0 mg Ozempic dose approved in USIGM Biosciences and Sanofi enter deal with USD 6bn potentialFDA requests 34-percent budget increaseSanofi gets first ever approval within Niemann-Pick as Japan green-lights drugCEO van de Winkel wants long tenure at GenmabOrphazyme gets another annual report extension approvedSanofi lifts sales potential of blockbuster drug to USD 14.5bnNew FDA requirements could provide opportunities for Genmab, CEO saysNovo Holdings eyes opportunities as biotech bubble burstsLundbeck enters licensing agreement for antidepressant in IndiaWorld's biggest audiologist conference to focus on OTC sales channelOrphazyme CEO stays silent in run-up to creditor meetingZealand Pharma appoints head of R&D as CEORestructuring gives embattled Orphazyme three paths to survival US legal appeal rejected in win for Novo NordiskGenmab CEO says Janssen should "show respect" as royalty strife nears conclusionNewly appointed Zealand Pharma CEO says commercial organization was too expensiveUS audiologists want clarity on OTC hearing aid returns policies Former Novo Nordisk CEO Lars Rebien opened factory in Russia – "I've been too naive"EMA advises clinical trial managers over impact of war in UkraineHead of US audiologist association thinks OTC could increase hearing loss awarenessOrphazyme reveals survival plan: Possible buyers and investors have been contactedOrphazyme confirms delisting in the USOrphazyme's creditors left without real optionsUS House of Representatives passes bill to cap insulin priceHERA calls for participation from life science industry GN Hearing CEO: OTC will increase price transparency on the hearing marketOrphazyme is in dialog with a number of potential suitors in search of rescueHearing Industries Association calls for more OTC regulationTop news from MedWatch this weekOrphazyme down to 20 employees after multiple firing roundsCEO of Novo Holdings: "We have executed the strategy we laid out when I joined"Analyst: Price cap on insulin is unlikely to affect drugmakersDemant has long-term expectations in ChinaGN Hearing CEO: Three reasons why Lively will soon be profitableFormer Novo CEO Lars Rebien appointed executive chair at FerringY-mabs resubmits cancer drug for marketing approval in the USWilliam Demant Invest increased its investment portfolio by USD 3.4bn in 2021The Lundbeck Foundation to focus exclusively on Danish biotechCEO of the Lundbeck Foundation defends share split proposalDemant wants more women in leadership – but won't set targets for its executive managementOlympus spins off scientific solutions divisionWorld's largest public-private antibiotic fund unveils first investmentsAnalyst comments on Novo Nordisk's record-breaking stock priceDeparting head of venture investments at the Lundbeck Foundation considers futureNovo Nordisk loses two senior staff to alternative antibiotics firmAudientes nominates former Microsoft veteran to board Orphazyme names the last day of trading in US Nanovi submits cancer biomarker for marketing approval in the USFDA grants Sanofi's blockbuster priority review in a new indicationZealand Pharma's restructuring plan has led to dismissals in DenmarkOrphazyme reveals new release date for 2021 reportZealand Pharma board re-electedEndoscopy president to leave Boston ScientificNordnet economist: Investors doubt future GN growthOrphazyme creditors approve restructuring planPfizer to acquire Reviral as RSV race continuesPfizer's RSV acquisition target is Novo Ventures portfolio companyGenmab loses royalties case against JanssenDanish Medicines Council considers fast-track schemeJanssen promises full focus on Darzalex after defeating Genmab in courtGenmab value drops by over USD 1.5bn after royalties defeatLundbeck finds new CFOTop news from MedWatch this weekBiontech and Genmab's collaboration goes deeper than previously saidLundbeck reports positive results from head-to-head study of antidepressant England and Wales reject Leo Pharma's eczema drugOrphazyme has dismissed co-founder and chief scientific officerLeo Pharma enters collaboration with Canadian biotech firmLundbeck sues competitor for infringing on patent rightsNovo Nordisk executive joins board of Finnish OrionEli Lilly and Almirall report promising results from phase III atopic eczema study Pharma lobby pledges to launch drugs on EU markets no later than two years after approvalNuheara submits self-fitting hearing aid for FDA approvalUS senators propose bill to force finalization of OTC rulesThe Novo Nordisk Foundation increases health focus in 2030 planBiontech to avoid big acquisitions despite billions on the bottom lineFerring VP steps down as chair of API manufacturerEvaxion co-founder takes step back from management, joins boardMedWatch closed for EasterGSK to buy cancer company for USD 1.9bn Boehringer Ingelheim enters collaboration on hearing loss treatment for up to USD 100mNovo Nordisk target price increased by five institutionsGN Hearing CEO: R&D organization is back on top formGenmab ponders next steps after preliminary cancer candidate resultsBavarian Nordic to start phase III with Covid-19 booster in JuneAmbu expands single-use endoscopy target market with new featureAmbu launches new gastroscope in Japan and EuropeJanssen's sales of Darzalex exceed expectationsLeo Pharma absorbs scrapped innovation hubs to streamline focusAnalyst: Darzalex sales could reach top end of projectionsLeo Pharma brings hair loss cream into phase IIBausch Health investigated by US Department of Justice over misleading marketing Bavarian begins phase III trial of RSV vaccine in older adultsCancer drug hope raises Genmab's spirits after legal defeatDemant lost ground at Veterans Affairs in MarchSnipr Biome brings first candidate to human trialSnipr Biome takes aim at antibiotic resistant bacteria in phase I trialSonion accuses Huawei and Sony of copying technologyUS institution changes share price target for three big Danish drugmakersAbbvie pulls plug on Swedish R&D partnershipNovo Nordisk initiates phase I trial of oral deviceOrifarm expands headquarters following huge acquisition Leo Pharma's climate targets receive science-based stamp of approval FDA rejects schizophrenia drug from TevaWHO recommends Pfizer's corona pillWestern medtech exports to Russia pick up speed againAging French population could boost Danish health exportsDanish Medicines Council makes five recommendations after April meetingAstellas Pharma ends development of dust mite allergy vaccineQufora expects French approval in 2022, trains sights on million-dollar businessTop news from MedWatch this weekEMA approves Novo Nordisk plan to store insulin at room temperature for longerCHMP recommends approval of Novo Nordisk's hemophilia drug for postpartum bleedingFour drugs recommended for approval by CHMP at April meetingAbundance of downgrades may put damper on accounting season, says analystLeo Pharma eczema drug makes Express Scripts preferred product listAnalyst: Increasing inflation will have multimillion-dollar impact on Novo Nordisk Malaria breakthrough hope rekindled by pandemic research after 30 years of stagnation Huge executive reshuffle at Saniona – firm to stop US activitiesNovo Nordisk foundation gives billions back to Denmark to fund developmentLundbeck VP joins board of migraine firmNovartis books multimillion-dollar sales of Genmab-developed drug in Q1Axsome Therapeutics steels itself for FDA rejection of migraine drugDanish life science foundations broke investment records in 2021Otonomy reports positive results with hearing loss candidate Demant to divest hearing implant division to CochlearDanish diabetes patients often prescribed expensive insulin firstAnalyst: Kesimpta sales from Novartis slightly over expectations Demant's hearing implant division struggled with recalls and pandemic pressureCochlear relieves Demant of loss-making implant divisionDemant CEO won't rule out dismissals following divestment of implant divisionBoston Scientific beats Q1 revenue expectations, except for endoscopy salesY-mabs CEO resigns with immediate effectMerck, Novo Nordisk spared from 1,500 suits over diabetes drug blamed for cancerDupixent drives sales advancement in Sanofi's first quarterEstron finds new CEONovo Nordisk to test key hemophilia drug in children in phase III Smith & Nephew books Q1 sales slightly better than projectionsEli Lilly upgrades full-year guidance due to solid growth in Q1Pent-up demand for hearing aids continues to boost sales in USNovo Nordisk upgrades full-year guidanceOrphazyme receives offers, begins negotiations with potential buyerNovo Nordisk reaches primary endpoint in phase III of once-weekly insulinNovo Nordisk subsupplier reinitiates Wegovy productionNovo Nordisk unveils Wegovy salesNovo Nordisk terminates program on innovative insulinNovo Nordisk aims to submit hemophilia drug for approval this yearOne day a month, Genmab employees are free to do as they pleaseTop news from MedWatch this weekNovo Nordisk drug becomes world's top-selling diabetes medicineBiomarin raises Voxzogo sales expectations againProduction limitations put a damper on Novo Nordisk's potential growthEargo enters million-dollar settlement with the United StatesLundbeck veteran reflects as he nears 25-year anniversary: "Don't forget your roots"Novo Nordisk remains coy over Wegovy blockbuster potentialBank says not to expect surprises in Demant's Q1 reportDemant predicts USD 14m impact of war in Ukraine in first ever quarterly reportNovo Nordisk confirms start of phase I robotic pill trial Eli Lilly wants to gain on Novo Nordisk's obesity leadDemant's Q1 results met with neutral response from analystNegative impact on Demant from Russia's war won't get any worse, says CEOInvestors asked Demant for more transparency – now they have itLeo Pharma takes hand eczema treatment into phase III Amplifon narrowly beats analyst consensus in first quarterNovo Nordisk initiates share buyback scheme and acquires shares from owner Analyst predicts favorable market conditions for ColoplastAmbu obtains CE mark for fifth generation single-use bronchoscope Bose to drop hearing aid business, media reportsAnalyst "positively surprised" by Demant's Q1 developmentEU proposes cross-border data space to strengthen health unionAnalyst: Bose hearing aid exit reflects market complexity GN Hearing beats analyst expectations for Q1WS Audiology's revenue grew by 20% in Q2 2021/2022GN Hearing CEO: Bose's exit spotlights complexity of hearing aid marketAnalysts flock to raise Novo Nordisk share price target following upgradeBavarian Nordic data shows booster shot protects against OmicronGN Hearing lets staff go to optimize supply chainWSA maintains guidance despite strong growth – CEO explains whyColoplast downgrades organic growth guidanceAmbu downgrades financial guidanceGN Hearing in talks with VA on new hybrid product categoryColoplast's biggest ever acquisition lands firm USD 40m in two monthsLundbeck poaches Zealand Pharma VPPotential buyers prepared to chase arimoclomol approval, Orphazyme deputy chair saysColoplast will not exit Russia, says CEOAmbu to reign in expectations after seventh downgrade since 2019Analyst will focus on phase III studies and travel vaccines in Bavarian reportTop news from MedWatch this weekColoplast postpones launch of ostomy care platform Bavarian Nordic maintains 2022 guidance Genmab enters agreement on cancer biomarker Bavarian terminates HPV and HBV collaboration with Janssen Denmark has paid out one-third of Bavarian Nordic's Covid-19 vaccine supportColoplast to issue notes for EUR 3.5bnBavarian will market Covid-19 vaccine on its own – but doesn't rule out future partnersEngland and Wales open for potential Leo Pharma recommendationZealand Pharma changes financing agreement Danish demand for ALK adrenaline pen surges, causing supply issuesEuropean innovation initiative puts Novo, Sanofi, and Eli Lilly in the same roomUS Democrats fighting insulin prices might falter as midterms nearAnalyst: Improved market conditions will support Lundbeck's key products in Q1Novo Nordisk enters research collaboration with Flagship PioneeringPfizer to acquire migraine firm for over USD 11bnLundbeck maintains guidance after exceeding expectations in Q1Novo Nordisk appoints new general manager for TurkiyeColoplast inherits possible USD 70m slipup from Atos MedicalLundbeck to delist in USDemant and GN gain ground at Veterans Affairs in AprilAnalyst will focus on royalties defeat and increased costs in Genmab's Q1 reportLundbeck CEO expects migraine market to grow following Pfizer's billion-dollar acquisitionEU migraine drug approval triggers multimillion-dollar bill for LundbeckSanofi reports data reinforcing efficacy of RSV candidateGenmab beats Q1 expectations and narrows full-year guidance rangeALK beats analyst expectations on all parametersGenmab throws in the towel – won't contest royalties rulingGenmab CEO on royalties defeat: "I'm sad and disappointed"Indian generic drugmaker settles lawsuit with Leo PharmaLundbeck to test Vyepti in direct comparison with competitorsALK reaches symbolic milestone as tablets generate half of revenuesMedWatch closed on Friday, May 13Zealand Pharma rescue pen books USD 0.6m revenue in Q1Orphazyme sells entire business to US biotech companyZealand Pharma CEO hopes for partnership news in coming months FDA approves Eli Lilly diabetes drugSonion chair retires as replacement takes overEargo gets second warning from Nasdaq for missing reportsNew EU regulation has made the medtech industry turn to the USOrphazyme didn't know buyer before negotiations beganEU to terminate vaccine agreement with ValnevaFuture uncertain for Orphazyme CEO as firm soldLundbeck has initiated phase I trial of acquired candidateSonova sales surpass analyst expectations in annual reportArkansas alleges insulin pricing plot involving Novo Nordisk, Eli Lilly and SanofiAnalyst: Strong Sonova advance indicates improved marketZealand Pharma sells insulin pump to Mannkind CorporationObesity rates increase to "epidemic" level in Europe, WHO warnsOrphazyme delays annual report again after striking deal with KempharmIssues at Novo Nordisk lead to shortage of fast-acting diabetes drugZealand Pharma stock soars after selling insulin pumpUS government exercises option to buy Bavarian smallpox vaccines for USD 119mAnalyst: US vaccine order secures future cash flow for BavarianALK execs rake in profits after exercising share optionsAnalyst predicts slow start for Leo Pharma's Adtralza in UK Almirall enters partnership with Inserm Transfert to research vitiligoIn a world of options, Genmab's CEO chose partnershipsDiabetes center CEO: New Eli Lilly drug is worthy opponent for Novo Nordisk's OzempicNovo Holdings establishes new firm managed by biotech veteransOrphazyme's creditors to vote on sales agreement at end of MayThousands of collaborative research papers with China pose threat to Europe, authorities worryBavarian lands monkeypox vaccine contract with unnamed European countryAlmirall and Evotec to collaborate on multiple severe skin disease targetsAudientes generates first-ever revenue in Q1Zealand Pharma reports positive phase III results against congenital hyperinsulinismAmbu appoints Britt Meelby Jensen new CEO Novo Nordisk regains Novorapid supply capacityALK CEO sells shares for USD 1.5mAmbu board had started headhunting process long before firing of CEOBritt Meelby Jensen wants to rebuild trust in AmbuAnalysts have great faith in incoming Ambu CEODanish Medicines Council rejects Novartis breast cancer drug Nine new drugs recommended for approval by CHMP at May meetingOutgoing Ambu CEO commends colleaguesTop news from MedWatch this weekSmallpox projects send stocks soaringPrivacy PolicyServiceAdvertisingOtherJobsSubscriptionJobchangeRegulationNewsHearing healthMedWatch.comRSSPharma & biotechAbout usTerms and conditionsContactMedtechArticlearchive
1